A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II
Phase: PHASE3
Conditions: Varicella
Sponsor: Merck Sharp & Dohme LLC

Official Protocol Title: 
NCT number: 
NCT03239873 
Document Date: 
26-OCT-2017
A Phase 3, Double-Blind, Randomized, Multicenter, Controlled 
Study to Evaluate the Immunogenicity, Safety, and Tolerability of 
VARIVAX™ Passage Extension 34 (PE34) Process Administered 
Concomitantly with M-M-R™ II

Product:  V210 
1
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK &
CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
SPONSOR:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 
(hereafter referred to as the Sponsor or Merck)
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey, 08889-0100, U.S.A.
Protocol-specific Sponsor Contact information can be found in the Investigator Trial File 
Binder (or equivalent).
TITLE:
A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the 
Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) 
Process Administered Concomitantly with M-M-R™ II
IND NUMBER:  0375
EudraCT NUMBER:  Not applicable
 
 
04S63N
 
 
055D6R

Product:  V210 
2
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
TABLE OF CONTENTS
SUMMARY OF CHANGES.................................................................................................. 9
1.0
TRIAL SUMMARY.................................................................................................. 11
2.0
TRIAL DESIGN........................................................................................................ 11
Trial Design ........................................................................................................... 11
2.1
Trial Diagram........................................................................................................ 12
2.2
3.0
OBJECTIVE(S) & HYPOTHESIS(ES).................................................................. 13
Primary Objective(s) & Hypothesis(es) .............................................................. 13
3.1
Secondary Objective(s) & Hypothesis(es)........................................................... 14
3.2
4.0
BACKGROUND & RATIONALE.......................................................................... 14
Background ........................................................................................................... 14
4.1
Pharmaceutical and Therapeutic Background .................................................... 14
4.1.1
Rationale................................................................................................................ 15
4.2
Rationale for the Trial and Selected Subject Population .................................... 15
4.2.1
Rationale for Dose Selection/Regimen............................................................... 15
4.2.2
Rationale for Endpoints ...................................................................................... 16
4.2.3
Immunogenicity Endpoints.......................................................................... 16
4.2.3.1
Safety Endpoints .......................................................................................... 16
4.2.3.2
Future Biomedical Research........................................................................ 17
4.2.3.3
Benefit/Risk ........................................................................................................... 17
4.3
5.0
METHODOLOGY ................................................................................................... 17
Entry Criteria........................................................................................................ 17
5.1
Diagnosis/Condition for Entry into the Trial ...................................................... 17
5.1.1
Subject Inclusion Criteria.................................................................................... 18
5.1.2
Subject Exclusion Criteria .................................................................................. 18
5.1.3
Subject Deferment Criteria (Before Vaccination 2) .................................... 20
5.1.3.1
Criteria for Excluding Subjects from Receiving Vaccination 2 .................. 21
5.1.3.2
Trial Vaccination(s) .............................................................................................. 22
5.2
Dose Selection .................................................................................................... 22
5.2.1
Dose Selection (Preparation) ....................................................................... 22
5.2.1.1
Timing of Dose Administration .......................................................................... 23
5.2.2
 
 
04S63N
 
 
055D6R

Product:  V210 
3
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Trial Blinding...................................................................................................... 23
5.2.3
Randomization or Vaccine Allocation ................................................................ 23
5.3
Stratification.......................................................................................................... 23
5.4
Concomitant Medications/Vaccinations (Allowed and Prohibited)................. 23
5.5
Rescue Medications & Supportive Care............................................................. 25
5.6
Diet/Activity/Other Considerations..................................................................... 25
5.7
Subject Withdrawal/Discontinuation Criteria................................................... 25
5.8
Discontinuation of Vaccination .......................................................................... 25
5.8.1
Withdrawal from the Trial .................................................................................. 26
5.8.2
Subject Replacement Strategy............................................................................. 26
5.9
Beginning and End of the Trial ........................................................................... 26
5.10
Clinical Criteria for Early Trial Termination ................................................... 26
5.11
6.0
TRIAL FLOW CHART ........................................................................................... 27
7.0
TRIAL PROCEDURES ........................................................................................... 29
Trial Procedures ................................................................................................... 29
7.1
Administrative Procedures.................................................................................. 29
7.1.1
Informed Consent......................................................................................... 29
7.1.1.1
7.1.1.1.1
General Informed Consent.................................................................... 29
7.1.1.1.2
Consent and Collection of Specimens for Future Biomedical 
Research................................................................................................ 30
Inclusion/Exclusion Criteria ........................................................................ 30
7.1.1.2
Subject Identification Card .......................................................................... 30
7.1.1.3
Medical History ........................................................................................... 30
7.1.1.4
Prior and Concomitant Medications Review ............................................... 30
7.1.1.5
7.1.1.5.1
Prior Medications.................................................................................. 30
7.1.1.5.2
Concomitant Medications..................................................................... 31
Assignment of Screening Number............................................................... 31
7.1.1.6
Assignment of Treatment/Randomization Number..................................... 31
7.1.1.7
Trial Compliance (Medication/Diet/Activity) ............................................. 31
7.1.1.8
Distribution of Electronic Vaccination Report Card (eVRC)...................... 31
7.1.1.9
Clinical Procedures/Assessments........................................................................ 32
7.1.2
Vaccine Administration ............................................................................... 32
7.1.2.1
7.1.2.1.1
Preparation of Trial Vaccine................................................................. 32
 
 
04S63N
 
 
055D6R

Product:  V210 
4
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
7.1.2.1.2
Administration of Trial Vaccines ......................................................... 32
7.1.2.1.3
General Precaution for Administration of Vaccine .............................. 33
7.1.2.1.4
Temperature Procedures ....................................................................... 33
7.1.2.1.5
Clinical Follow-up ................................................................................ 33
Laboratory Procedures/Assessments .................................................................. 34
7.1.3
Laboratory Immunogenicity Evaluations .................................................... 34
7.1.3.1
7.1.3.1.1
Blood Sample Collection for Antibody Measurement ......................... 34
7.1.3.1.2
Detection of IgG Antibody to VZV (gpELISA) ................................... 34
Future Biomedical Research Samples ......................................................... 35
7.1.3.2
Other Procedures................................................................................................. 35
7.1.4
Withdrawal/Discontinuation........................................................................ 35
7.1.4.1
7.1.4.1.1
Withdrawal From Future Biomedical Research ................................... 35
7.1.4.1.2
Lost to Follow-up.................................................................................. 36
Subject Blinding/Unblinding ....................................................................... 36
7.1.4.2
Calibration of Critical Equipment................................................................ 37
7.1.4.3
Visit Requirements.............................................................................................. 37
7.1.5
Screening...................................................................................................... 37
7.1.5.1
Vaccination Visits........................................................................................ 37
7.1.5.2
Post-trial (Visit 4: Follow-up Visit, and Visit 5: Follow-up Phone Call).... 37
7.1.5.3
Assessing and Recording Adverse Events .......................................................... 37
7.2
Definition of an Overdose for This Protocol and Reporting of Overdose to 
7.2.1
the Sponsor.......................................................................................................... 38
Immediate Reporting of Adverse Events to the Sponsor.................................... 39
7.2.2
Serious Adverse Events ............................................................................... 39
7.2.2.1
Events of Clinical Interest............................................................................ 40
7.2.2.2
Evaluating Adverse Events ................................................................................. 40
7.2.3
Sponsor Responsibility for Reporting Adverse Events ...................................... 43
7.2.4
8.0
STATISTICAL ANALYSIS PLAN ........................................................................ 43
Statistical Analysis Plan Summary ..................................................................... 43
8.1
Responsibility for Analyses/In-house Blinding .................................................. 44
8.2
Hypotheses/Estimation ......................................................................................... 45
8.3
Analysis Endpoints ............................................................................................... 45
8.4
Immunogenicity Endpoints................................................................................. 45
8.4.1
 
 
04S63N
 
 
055D6R

Product:  V210 
5
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Safety Endpoints ................................................................................................. 45
8.4.2
Analysis Populations............................................................................................. 45
8.5
Immunogenicity Analysis Populations ............................................................... 45
8.5.1
Per-protocol Population ............................................................................... 45
8.5.1.1
Full Analysis Set.......................................................................................... 46
8.5.1.2
Safety Analysis Population ................................................................................. 46
8.5.2
Statistical Methods................................................................................................ 47
8.6
Statistical Methods for Immunogenicity Analysis.............................................. 47
8.6.1
Noninferiority of Postvaccination 1 VZV Antibody Response (Primary 
8.6.1.1
Hypothesis 1)............................................................................................... 47
Noninferiority of Postvaccination 1 VZV Antibody GMT (Primary 
8.6.1.2
Hypothesis 2) ............................................................................................... 47
Acceptability of Immune Response (Primary Hypothesis 3) ...................... 48
8.6.1.3
Secondary Summaries.................................................................................. 48
8.6.1.4
Statistical Methods for Safety Analysis .............................................................. 51
8.6.2
Summaries of Baseline Characteristics, Demographics, and Other Analyses.... 53
8.6.3
Interim Analyses ................................................................................................... 54
8.7
Multiplicity ............................................................................................................ 54
8.8
Sample Size and Power Calculations .................................................................. 54
8.9
Sample Size and Power for Immunogenicity Analyses ...................................... 54
8.9.1
Sample Size and Power for Safety Analyses ...................................................... 55
8.9.2
Subgroup Analyses ............................................................................................... 56
8.10
Extent of Exposure................................................................................................ 57
8.11
9.0
LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ................................................................................................................. 57
Investigational Product ........................................................................................ 57
9.1
Packaging and Labeling Information ................................................................. 57
9.2
Clinical Supplies Disclosure................................................................................. 58
9.3
Storage and Handling Requirements.................................................................. 58
9.4
Discard/Destruction/Returns and Reconciliation .............................................. 58
9.5
Standard Policies................................................................................................... 58
9.6
10.0
ADMINISTRATIVE AND REGULATORY DETAILS....................................... 58
Confidentiality....................................................................................................... 58
10.1
 
 
04S63N
 
 
055D6R

Product:  V210 
6
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Confidentiality of Data ....................................................................................... 58
10.1.1
Confidentiality of Subject Records ..................................................................... 59
10.1.2
Confidentiality of Investigator Information........................................................ 59
10.1.3
Confidentiality of IRB/IEC Information............................................................. 60
10.1.4
Compliance with Financial Disclosure Requirements....................................... 60
10.2
Compliance with Law, Audit and Debarment ................................................... 60
10.3
Compliance with Trial Registration and Results Posting Requirements ........ 62
10.4
Quality Management System............................................................................... 62
10.5
Data Management................................................................................................. 63
10.6
Publications ........................................................................................................... 63
10.7
11.0
LIST OF REFERENCES......................................................................................... 65
12.0
APPENDICES........................................................................................................... 67
Merck Code of Conduct for Clinical Trials........................................................ 67
12.1
Collection and Management of Specimens for Future Biomedical 
12.2
Research................................................................................................................. 69
Approximate Blood Volumes Collected by Trial Visit and by Sample 
12.3
Types ...................................................................................................................... 73
Scripted Questionnaire to Be Used by Site Personnel to Obtain Serious 
12.4
Adverse Experience and Medically Attended Adverse Event Information .... 74
List of Abbreviations and Definitions of Terms................................................. 76
12.5
13.0
SIGNATURES........................................................................................................... 78
Sponsor's Representative ..................................................................................... 78
13.1
Investigator............................................................................................................ 78
13.2
 
 
04S63N
 
 
055D6R

Product:  V210 
7
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
LIST OF TABLES
Table 1
Trial Vaccinations................................................................................................. 22
Table 2
Evaluating Adverse Events................................................................................... 41
Table 3
Analysis Strategy for Key Immunogenicity Variables......................................... 50
Table 4
Analysis Strategy for Safety Parameters............................................................... 52
Table 5
Differences in Incidence of Adverse Event Rates between the Two 
Vaccination Groups That Can be Detected With an ~80% Probability and a 
Two-Sided Significance Level of 0.05 Postvaccination 1.................................... 55
Table 6
Differences in Incidence of Adverse Event Rates Between the Two 
Vaccination Groups That Can be Detected With an ~80% Probability and a 
Two-Sided Significance Level of 0.05 Postvaccination 2.................................... 56
Table 7
Product Descriptions............................................................................................. 57
 
 
04S63N
 
 
055D6R

Product:  V210 
8
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
LIST OF FIGURES
Figure 1
Trial Diagram...................................................................................................... 12
 
 
04S63N
 
 
055D6R

Product:  V210 
9
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
SUMMARY OF CHANGES
PRIMARY REASON(S) FOR THIS AMENDMENT:
Section Number (s)
Section Title(s)
Description of Change (s)
Rationale
7.2.2.1
Serious Adverse Events
Updated
that serious adverse 
events (SAEs) should be reported 
from the time period beginning at 
treatment 
allocation/randomization  through 
6 months (~180 days) following 
the second vaccination (instead of 
through 14 days [42 days for live 
attenuated vaccines] after each 
vaccination).
The reporting period of SAEs has 
been amended to remain consistent 
with the reporting standards within 
the VARIVAX™program.
4.2.3.2
Safety Endpoints
Added unsolicited injection-site 
reactions 
from 
the 
eVRC, 
occurring on Days 1 through 42 
after each vaccination as a safety 
parameter for the trial.
This section has been amended to 
clarify that unsolicited injection-
site reactions occurring on Days 1 
through 42 are collected as a safety 
parameter for the trial.  As detailed 
in the previously issued Protocol 
Clarification 
Letter, 
unsolicited 
injection-site 
reactions 
were 
always intended to be collected in 
this trial; however, the previous 
version of the protocol did not list 
unsolicited injection-site reactions 
in this section of the protocol.  
This change provides consistency 
within the protocol.
 
 
04S63N
 
 
055D6R

Product:  V210 
10
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Section Number (s)
Section Title(s)
Description of Change (s)
Rationale
7.1.2.1.2
Administration of Trial 
Vaccines
Removed the requirement that all 
used and unused vaccine vials 
should be returned to the Sponsor 
upon completion of the trial.
This change is being made to allow 
sites to dispose of used vaccine 
vials at sites that have appropriate 
standards and processes in place.
6.0
Trial Flow Chart
Clarified 
that 
parents/legally 
acceptable representative should 
not 
record 
oral 
or 
otic 
temperatures.
This change is being made to 
provide 
clarity 
regarding 
the 
methodology 
of 
temperature 
assessment 
by 
parents/legally 
acceptable representatives.
7.1.2.1.4
Temperature Procedures
ADDITIONAL CHANGE(S) FOR THIS AMENDMENT:
No additional changes.
 
 
04S63N
 
 
055D6R

Product:  V210 
11
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
1.0 TRIAL SUMMARY
Abbreviated Title
Immunogenicity and Safety of VARIVAX™Passage Extension 34 
(PE34) Process in Children
Sponsor Product Identifiers
V210
Varicella virus vaccine live (Oka/Merck)
Trial Phase
Phase 3
Clinical Indication
Active immunization for the prevention of varicella in individuals 
12 months of age and older
Trial Type
Interventional
Type of control
Active control without placebo
Route of administration
Subcutaneous
Trial Blinding
Double-blind
Vaccination Groups
Healthy children who are 12 to 23 months of age will be randomized 
to receive 2 doses of either VARIVAX™ Passage Extension 34 
(PE34) process (Group 1) or VARIVAX™ (2016 commercial 
product) (Group 2), each given approximately 3 months apart,
concomitantly with M-M-R™ II
Number of trial subjects
Approximately 600 subjects will be enrolled.
Estimated duration of trial
The Sponsor estimates that the trial will require approximately 
18 months from the time that written informed consent is provided for 
the first subject until the last subject’s last study-related phone call or 
visit. For purposes of analysis and reporting, the overall study ends 
when the Sponsor receives the last serology assay result.
Duration of Participation
Each subject will participate in the trial for approximately 9 months
from the time the subject/legally acceptable representative signs the 
informed consent form through the final contact.
A list of abbreviations used in this document can be found in Section 12.4.
2.0 TRIAL DESIGN
Trial Design
2.1
This is a randomized, comparator-controlled, multicenter, double-blind trial to evaluate the 
safety, tolerability, and immunogenicity of the VARIVAX™ (varicella virus vaccine live,
Oka/Merck; V210, Merck) Passage Extension 34 (PE34) process compared with the 
VARIVAX™ (2016 commercial product) in healthy children 
who are between 12 to 
23 months of age.
Approximately 600 subjects will be enrolled. Subjects will be randomized into 1 of 2 
vaccination groups (ratio 1:1) with approximately 300 subjects per group.  Group 1 will 
receive 2 doses of VARIVAX™ PE34 process, given concomitantly with M-M-R™II
[measles, mumps, and rubella virus vaccine live, Merck], approximately 3 months apart.  
Randomization Ratio
1:1
 
 
04S63N
 
 
055D6R

Product:  V210 
12
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Group 2 will receive 2 doses of VARIVAX™ (2016 commercial product), given 
concomitantly with M-M-R™ II, approximately 3 months apart.
The enrollment period for the trial is expected to be approximately 9 months.  Once enrolled, 
the total duration of the trial for a subject (from first visit to last contact) will be 
approximately 9 months.  A subject is considered to have completed the trial when (1) both 
scheduled trial vaccinations are received, (2) both blood samples have been collected, and 
(3) the 42-day safety data after each vaccination have been collected.  A subject is considered 
to have completed the extended safety follow-up when the last protocol-specified phone call 
is completed, and all safety data have been collected.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each 
procedure are provided in Section 7.0 – Trial Procedures.
Trial Diagram
2.2
The trial design is depicted in Figure 1.
Figure 1
Trial Diagram
 
 
04S63N
 
 
055D6R

Product:  V210 
13
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
3.0 OBJECTIVE(S) & HYPOTHESIS(ES)
The following objectives will be evaluated in healthy children aged 12 to 23 months.
Primary Objective(s) & Hypothesis(es)
3.1
1) Objective:  To demonstrate that a single dose of VARIVAX™PE34 process induces 
varicella-zoster virus (VZV) antibody responses 6 weeks Postvaccination 1 that are 
noninferior to those induced by VARIVAX™ 2016 commercial product.
The primary endpoints for measuring the VZV antibody responses are the response 
rate and the geometric mean titer (GMT).  The response rate is defined as the 
proportion of subjects with VZV antibody titer ≥5 glycoprotein enzyme-linked 
immunosorbent assay (gpELISA) units/mL 6 weeks Postvaccination 1
among 
subjects who were seronegative to VZV (titers <1.25 gpELISA units/mL) at baseline.
Hypotheses:
(1)  Six weeks Postvaccination 1, VARIVAX™PE34 process induces VZV antibody 
responses that are noninferior to those induced by VARIVAX™ (2016 commercial 
product), as measured by the response rate.
(The statistical criterion for noninferiority of the response rate corresponds to the 
lower bound of the 2-sided 95% confidence interval [CI] on the difference in 
response rates [VARIVAX™ PE34 process minus VARIVAX™ 2016 commercial 
product] excluding a decrease of 10 percentage points or more.)
(2)  Six weeks Postvaccination 1, VARIVAX™PE34 process induces VZV antibody 
responses that are noninferior to those induced by VARIVAX™ (2016 commercial 
product), as measured by the GMT.
(The statistical criterion for noninferiority of the GMT corresponds to the lower 
bound of the 2-sided 95% CI on the GMT ratio [VARIVAX™ PE34
process/VARIVAX™ 2016 commercial product] being >0.67.)
2) Objective:  To demonstrate that a single dose of VARIVAX™ PE34 process induces 
an acceptable VZV antibody response 6 weeks Postvaccination 1.
Hypothesis:
(3) Six weeks Postvaccination 1, VARIVAX™ PE34 process induces an acceptable 
VZV antibody response, as measured by the response rate.
(The statistical criterion for an acceptable antibody response corresponds to the lower 
bound of the 95% CI for the response rate to VZV in the group receiving 
VARIVAX™ PE34 process being >76.0%.)
 
 
04S63N
 
 
055D6R

Product:  V210 
14
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Secondary Objective(s) & Hypothesis(es)
3.2
1) Objective:  To assess the safety and tolerability of the first and second doses of 
VARIVAX™ PE34 process.
2) Objective:  To summarize the VZV antibody responses after a single dose of 
VARIVAX™ PE34 process and after a single dose of VARIVAX™ (2016 
commercial product). The VZV immunogenicity data will be summarized for the 
antibody response rates, seroconversion rates and GMTs, along with the associated 
95% CI for these parameters. No formal testing will be conducted.
Success for the trial requires success on the 3 hypotheses based on the primary objectives.
4.0 BACKGROUND & RATIONALE
Background
4.1
Refer to the package insert and Investigator’s Brochure for detailed background information 
on VARIVAX™.
Pharmaceutical and Therapeutic Background
4.1.1
Varicella is a generalized illness that has an incubation period of about 12 to 16 days and is 
highly contagious.  It is characterized by a papulovesicular rash that typically resolves in 5 to 
6 days.  The most common complications of varicella include secondary bacterial infection, 
encephalitis, Reye syndrome, pneumonia, and death.  Less common complications include 
nephritis, arthritis, orchitis, uveitis, thrombocytopenia, and purpura fulminans.  Although 
immunity after varicella infection is generally long-lasting, the virus may persist in latent 
form in the peripheral nerve tissue (ganglia).  Herpes zoster ([HZ] or shingles) may develop 
as a result of the reactivation of latent VZV.
VARIVAX™is a vaccine indicated for active immunization for the prevention of varicella in 
individuals 12 months of age and older.
Before the introduction of a varicella vaccine (VARIVAX™), an estimated 4 million cases of 
varicella occurred annually in the United States [1], resulting in 10,000 hospitalizations and 
over 100 deaths [2] [3]. VARIVAX™ was licensed in 1995 after studies demonstrated 
single-dose efficacy of 70% to 95% against clinical disease and 95% against severe disease 
over a 7- to 10-year follow-up period [4].  Following licensure, vaccine coverage has
increased to an estimated 90% of the pediatric population in the United States [5] [6], thereby 
reducing varicella incidence by up to 91% [5] and varicella-related hospitalizations by 75% 
to 88% [7] [8].  During the first 12 years after licensure of VARIVAX™in the United States, 
varicella-related mortality decreased by 88%, including a 97% reduction in individuals 
younger than 20 years of age, and a 96% reduction in individuals younger than 50 years of 
age [9]. 
Recent epidemiologic studies have demonstrated that VARIVAX™affords 
long-term protection over 14 years against varicella and also imparts herd immunity to 
unvaccinated individuals in settings where vaccine adoption is widespread [10].  Currently, 
 
 
04S63N
 
 
055D6R

Product:  V210 
15
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
the Advisory Committee on Immunization Practices (ACIP) in the United States
recommends (as of 2006) that a 2-dose regimen be administered in childhood [11].
Rationale
4.2
Rationale for the Trial and Selected Subject Population
4.2.1
Following the recommendation of a 2-dose varicella vaccination schedule by the ACIP, and 
the approval of other VZV-containing products (ZOSTAVAX™[zoster vaccine live, Merck] 
and ProQuad™[measles, mumps, rubella, and varicella virus vaccine live, Merck]), the 
demand for VZV-containing vaccines has increased.
The VARIVAXPE34 process will extend the availability of VZV (Oka/Merck)-containing 
vaccines and is not expected to change the safety profile or effectiveness of the vaccine.
The purpose of this Phase 3, randomized, double-blind, multicenter, controlled trial is to 
assess the immunogenicity, safety, and tolerability of VARIVAX™ PE34 process in 
comparison with VARIVAX™ (2016 commercial product).
VARIVAX™ is indicated for active immunization for the prevention of varicella in 
individuals 12 months of age and older.
This trial will be performed in healthy children who are between 12 to 23 months of age, 
which is the recommended age group for the first dose of VZV-containing vaccine.
Rationale for Dose Selection/Regimen
4.2.2
Both VARIVAX™ PE34 process and VARIVAX™ (2016 commercial product) are 
administered subcutaneously as a 0.5-mL dose.  The dose of VARIVAX™ PE34 process is 
the same as for VARIVAX™ (2016 commercial product) because VARIVAX™ PE34 is 
formulated in such a way to contain the same minimum potency at the time of release.
All subjects enrolled in this trial will receive 2 doses of trial vaccine administered 
concomitantly with M-M-R™ II.  This is consistent with the recommended regimens in the 
United States and European Union (EU).  In the United States, the ACIP recommends a 
2-dose regimen of varicella vaccines.  A minimum interval of 3 months (90 days) is 
recommended between each dose of VZV-containing vaccines when administered to 
children.  In the EU, at least 1 month must elapse between the first and second dose of any 
live viral attenuated vaccine.  In both the United States and the EU, varicella vaccine can be 
administered to children as a 2-dose series.  In regions where vaccination of toddlers against 
varicella is the standard of care, VZV-containing vaccines are typically administered 
concurrently with measles-mumps-rubella-containing vaccines.
 
 
04S63N
 
 
055D6R

Product:  V210 
16
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Rationale for Endpoints
4.2.3
Immunogenicity Endpoints
4.2.3.1
The immunogenicity endpoints for this trial are consistent with those used in previous 
clinical studies of VARIVAX™. 
The primary time point for the assessment of 
immunogenicity analyses will be at 6 weeks Postvaccination 1.
The presence of VZV-specific antibodies will be assessed by gpELISA.  The gpELISA will 
be used to detect antibody (immunoglobulin G [IgG]) to VZV pre- and postvaccination with 
VZV-containing vaccines.  The gpELISA assay is the primary assay used by the Sponsor to 
evaluate the serologic response to VZV vaccines; the performance characteristics of this 
assay have been well established in previous clinical trials.  The response rate for VZV is 
defined as the proportion of subjects with a postvaccination VZV antibody titer ≥5 gpELISA 
units/mL for subjects who were seronegative to VZV (titer <1.25 gpELISA units/mL) at 
baseline.  An antibody titer ≥5 gpELISA units/mL correlates with long-term protection [12].
Safety Endpoints
4.2.3.2
Throughout the clinical development program VARIVAX™ has demonstrated an acceptable 
safety profile in children. Moreover, across dose ranges and manufacturing processes, 
aggregate safety data from the varicella clinical development program demonstrate the 
consistency of the safety profile of VARIVAX™, with similar rates of local and systemic 
adverse experiences and temperature data.
Additionally, in clinical studies that have
evaluated the concomitant administration of VARIVAX™ with M-M-R™ II, concomitant 
use did not adversely affect the safety profile of either vaccine.
In clinical studies using a 2-dose regimen of VZV-containing vaccine in children, the 
incidence of injection-site reactions after vaccination was generally higher Postvaccination 2 
than Postvaccination 1, although the injection-site reactions were short in duration and mild 
in intensity and size; whereas, significantly lower incidences of elevated temperatures and 
noninjection-site varicella-like rashes were observed Postvaccination 2 compared with 
Postvaccination 1.
As with previous VARIVAX™studies, the postvaccination safety follow-up period will be 
42 days after each vaccination. 
The safety parameters for this trial will include the 
proportion of subjects with the following: 
1) elevated temperatures ≥102.2°F [≥39.0°C] oral equivalent) up to 42 days after each 
trial vaccination;
2) varicella-like, zoster-like, measles-like, or rubella-like rashes or mumps-like 
symptoms occurring up to 42 days after each trial vaccination;
3) solicited injection-site reactions (using the electronic vaccination report card 
[eVRC]), such as redness, swelling, and pain/tenderness/soreness, occurring within 
5 days after each trial vaccination;
 
 
04S63N
 
 
055D6R

Product:  V210 
17
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
4) all unsolicited injection-site reactions occurring on Days 1 through 42 after each trial 
vaccination;
5) systemic adverse experiences up to 42 days after each trial vaccination;
6) serious adverse experiences throughout the trial duration; and
7) medically attended adverse events from Day 133 through Day 271.
Future Biomedical Research
4.2.3.3
The Sponsor will conduct Future Biomedical Research on specimens consented for future 
biomedical research during this clinical trial.  This research may include genetic analyses 
(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or 
the measurement of other analytes, depending on which specimens are consented for future 
biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from 
appropriately consented subjects. The objective of collecting/retaining specimens for Future 
Biomedical Research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
subjects receive the correct dose of the correct drug/vaccine at the correct time.  The details 
of this Future Biomedical Research sub-trial are presented in Section 12.2 – Collection and 
Management of Specimens for Future Biomedical Research.
Benefit/Risk
4.3
Subjects in this trial are expected to receive the same benefit, as established with 
VARIVAX™ and M-M-R™ II. The change in production process is not expected to affect 
the benefit/risk ratio.
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accompanying VARIVAX™ package insert and 
Investigator’s Brochure, M-M-R™II package insert, and informed consent documents.
5.0 METHODOLOGY
Entry Criteria
5.1
Diagnosis/Condition for Entry into the Trial
5.1.1
Healthy children who are between 12 and 23 months of age (inclusive) will be enrolled in 
this trial.
 
 
04S63N
 
 
055D6R

Product:  V210 
18
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Subject Inclusion Criteria
5.1.2
In order to be eligible for participation in this trial, the subject must:
1. Be between 12 to 23 months of age upon receipt of the first trial vaccination 
(subject is able to enroll up to 1 day before 24 months of age).
2. Be in good health based on medical history.
3. Have a negative clinical history for varicella, HZ, measles, mumps, and rubella.
4. Be able to complete all scheduled visits and comply with the trial procedures.
5. Have a parent/legally acceptable representative who understands the trial 
procedures, alternate treatments available, and risks involved with the trial and 
voluntarily agree to participate in the trial by providing written informed consent.
6. Have a parent/legally acceptable representative who is able to read, understand, 
and complete the eVRC.
7. Have a parent/legally acceptable representative who also acknowledges that he or 
she:
a.
will attend all scheduled visits
b. will comply with the trial procedures, and
c.
will have access to a telephone and be willing to complete the safety 
follow-up phone call.
8. The subject’s parent/legally acceptable representative may also provide written 
informed consent/assent for Future Biomedical Research.  However, the subject 
may participate in the main trial without participating in Future Biomedical 
Research.
Subject Exclusion Criteria
5.1.3
The subject must be excluded from participating in the trial if the subject:
*If the subject meets any of the exclusion criteria marked with an asterisk (*), the Day 1 visit 
may be rescheduled for a time when these exclusion criteria are no longer met; however, 
the subject would only be permitted to continue with a delayed vaccination if the visit can 
be performed within 7 days of consent.
1. Has received any measles-, mumps-, rubella-, or VZV-containing vaccine, either 
alone or in any combination, at any time before the trial, or is anticipated to 
receive any of these vaccines, either alone or in any combination, during the trial.
 
 
04S63N
 
 
055D6R

Product:  V210 
19
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
2. Has any congenital or acquired immune deficiency, neoplastic disease, or 
depressed immunity, including those resulting from corticosteroid use (see 
Exclusion Criterion #3 and Section 5.5 – Concomitant Medications) or other 
immunosuppressive therapy.
3. Has received 1) systemic immunomodulatory steroids (no more than the 
equivalent of 2 mg/kg total daily dose of prednisone or >20 mg/day of prednisone 
or equivalent for subjects weighing >10 kg) for more than 7 consecutive days
within 
3 months 
before
entering 
trial, 
or 
2) any 
dose 
of 
systemic 
immunomodulatory steroids within 7 days before entering trial, or 3) is expected 
to require systemic immunomodulatory steroids during the course of the trial.
Exception:  Subjects who require nonsystemic steroids (e.g., topical, ophthalmic, 
inhaled) will be eligible for vaccination.
4. Has any blood dyscrasias, leukemia, lymphomas of any type, or other malignant 
neoplasms affecting the bone marrow or lymphatic systems.
5. Has a history of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, 
egg proteins (egg or egg products), chicken proteins, or any component of 
VARIVAX™ or M-M-R™ II, as stated in the package inserts.
6. *Has received salicylates (e.g., aspirin or any aspirin-containing products) within 
14 days before vaccination.
7. *Has had an exposure to varicella, HZ, measles, mumps, or rubella in the last 
4 weeks before trial vaccination involving:
a.
Continuous household contact, or
b.
Playmate contact (generally >1 hour of indoor play), or
c.
Hospital contact (in the same 2- to 4-bed room or in adjacent beds in a 
large ward or prolonged face-to-face contact with an infectious staff 
member or patient), or
d.
Contact with a newborn whose mother had an onset of chickenpox within 
≤5 days before delivery or within 48 hours after delivery.
8. *Was vaccinated with a licensed, inactivated (nonlive) vaccine (e.g., inactivated 
poliovirus [IPV], Diphtheria, Tetanus, and Acellular Pertussis [DTaP], 
Haemophilus influenzae type b [Hib]) within 14 days or less before any dose of 
the trial vaccines or is expected to be vaccinated during the 42-day safety follow-
up period after each trial vaccination.
9. *Was vaccinated with any licensed live vaccine within ≤30 days before any dose 
of the trial vaccines or is expected to be vaccinated within the 42-day safety 
follow-up period after each trial vaccination.
 
 
04S63N
 
 
055D6R

Product:  V210 
20
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
10. *Has had a recent (within 72 hours) history of febrile illness (102.2°F [39.0C] 
oral equivalent) before the trial vaccination. Temperature may be converted to 
oral equivalent by adding 1.0°F to axillary temperatures and subtracting 1.0°F 
from rectal temperatures.
11. Has received immunoglobulin, a blood transfusion, or blood-derived products 
(does not include autologous blood/blood products) within 5 months before 
vaccination or plans to receive these products while enrolled in this trial.
12. Has a history of seizure disorder, including single febrile seizure.
13. Has a history of thrombocytopenia.
14. Was born to a human immunodeficiency virus (HIV)-infected mother.
15. Has a diagnosis of active untreated tuberculosis.
16. Is currently participating in (30 days or less before enrollment) or scheduled to 
participate in any other clinical trial other than a surveillance trial during the 
planned trial period for this trial.
17. Has any other underlying medical condition that, in the opinion of the 
investigator, may interfere with the evaluation of trial objectives.
18. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling 
or child) who is investigational site or Sponsor staff directly involved with this 
trial.
Subject Deferment Criteria (Before Vaccination 2)
5.1.3.1
These subject deferment criteria must be reviewed for each subject before Vaccination 2 to 
ensure that none of the criteria apply to the subject, and/or that Vaccination 2 is deferred for 
the subject for an appropriate period of time.  The subject would only be permitted to 
continue with a delayed vaccination if the visit can be performed within the allowed window.
The subject should be deferred from continuing in the trial if the subject:
19. Has had exposure to varicella or HZ Postvaccination 1 (defer Vaccination 2 until 
4 weeks after the exposure):
a.
Continuous household contact, or
b. Playmate contact (generally >1 hour of indoor play), or
c.
Hospital contact (in same 2- to 4-bed room or adjacent beds in a large ward or 
prolonged face-to-face contact with an infectious staff member or patient), or
d. Contact with a newborn whose mother had onset of chickenpox within 
≤5 days before delivery or within 48 hours after delivery.
20. Has had exposure to measles, mumps, or rubella since Vaccination 1 (defer 
Vaccination 2 until 4 weeks after exposure).
 
 
04S63N
 
 
055D6R

Product:  V210 
21
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
21. Has had recent (within 72 hours) history of febrile illness (≥102.2°F [39.0°C] oral 
equivalent) before the trial vaccination (defer Vaccination 2 until >72 hours after 
resolution of febrile illness). Temperature may be converted to oral equivalent by 
adding 1.0°F to axillary temperatures and subtracting 1.0°F from rectal 
temperatures.
22. Has received any dose of systemic immunomodulatory steroids within 7 days 
before Vaccination 2 (defer Vaccination 2 until a minimum of 7 days after 
systemic immunomodulatory steroids).
23. Has had any licensed inactivated vaccine administered since Vaccination 1 (defer 
Vaccination 2 until a minimum of 15 days after nontrial vaccination[s]).
24. Has had any licensed live vaccine administered since Vaccination 1 (defer 
Vaccination 2 until a minimum of 31 days after nontrial vaccination[s]).
25. Has had receipt of salicylates (e.g., aspirin or any aspirin-containing products) 
since Vaccination 1 (defer Vaccination 2 until 14 days after taking medication).
26. Has had any medical condition that, in the opinion of the investigator, may 
interfere with the evaluation of the trial objectives. (The amount of time 
Vaccination 2 is deferred will be determined by the investigator.)
Criteria for Excluding Subjects from Receiving Vaccination 2
5.1.3.2
These subject exclusion criteria must be reviewed for each subject before Vaccination 2 to 
ensure that none of the criteria apply to the subject.
The subject must be excluded from receiving Vaccination 2 if the subject:
27. Has had any immunoglobulin, nonautologous blood,
or blood products 
administered Postvaccination 1.
28. Has had any nontrial measles-, mumps-, rubella-, or VZV-containing vaccine 
administered Postvaccination 1.
29. Has received systemic immunomodulatory steroids (no more than the equivalent 
of >2 mg/kg total daily dose of prednisone or equivalent or >20 mg/day of 
prednisone or equivalent for subjects weighing >10 kg) for more than 
7 consecutive days Postvaccination 1.
30. Has any blood dyscrasias, leukemia, lymphomas of any type, or other malignant 
neoplasms affecting the bone marrow or lymphatic systems diagnosed 
Postvaccination 1.
31. Has had any acquired or congenital immunodeficiency or active tuberculosis 
diagnosed Postvaccination 1.
32. Has had the occurrence of varicella infection Postvaccination 1.
33. Has had a vaccine-related allergic or anaphylactoid reaction reported 
Postvaccination 1.
 
 
04S63N
 
 
055D6R

Product:  V210 
22
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
34. Has enrolled in any other clinical trial other than a surveillance trial
Postvaccination 1.
35. Has had a seizure, including a febrile seizure, Postvaccination 1.
36. Has had thrombocytopenia Postvaccination 1.
Trial Vaccination(s)
5.2
The vaccines to be used in this trial are outlined below in Table 1.
Table 1
Trial Vaccinations
Vaccine
Dose/Potency
Dose 
Frequency
Route 
of 
Administration
Vaccination 
Regimen
Use 
VARIVAX™ PE34 
process (Group 1)
0.5 mL after 
reconstitution
2 doses; 
3 months 
between 
each dose
Subcutaneous
injection
Visit 1 (Day 1) and 
Visit 3 (Week 13 
[Days 91-105])
Investigational
VARIVAX™ (2016 
commercial product) 
(Group 2)
0.5 mL after 
reconstitution
2 doses; 
3 months 
between 
each dose
Subcutaneous
injection
Visit 1 (Day 1) and 
Visit 3 (Week 13 
[Days 91-105])
Standard of care
M-M-R™ II
(Groups 1 and 2)
0.5 mL after 
reconstitution
2 doses; 
3 months 
between 
each dose
Subcutaneous
injection
Visit 1 (Day 1) and 
Visit 3 (Week 13 
[Days 91-105])
Standard of care
Vials of vaccine will be labeled with component identification numbers (CIDs). Care should 
be taken to ensure that each subject receives the appropriate clinical materials labeled with 
their specific CID.
Trial vaccinations are given on the day of randomization or as close as possible to the date on
which the subject is allocated/assigned. All supplies indicated in Table 1 above will be 
provided centrally by the Sponsor.
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and any applicable laws and regulations.
Dose Selection
5.2.1
Dose Selection (Preparation)
5.2.1.1
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  There are no specific calculations or evaluations required to be 
performed in order to administer the proper dose to each subject.
 
 
04S63N
 
 
055D6R

Product:  V210 
23
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Timing of Dose Administration
5.2.2
Subjects will be randomized to 1 of 2 vaccination groups to receive either two 0.5-mL 
subcutaneous doses of VARIVAX™ PE34 process (Group 1) or two 0.5-mL subcutaneous 
doses of VARIVAX™ (2016 commercial product) (Group 2) approximately 3 months apart.  
Dose 1 will be administered at Visit 1 on Day 1 of the trial, and Dose 2 will be administered 
at Visit 3 (Week 13 [Days 91-105]). 
Each dose of VARIVAX™ PE34 process and 
VARIVAX™ (2016 commercial product) will be administered concomitantly with 
M-M-R™ II.
Trial Blinding 
5.2.3
A double-blinding technique with in-house blinding will be used.  VARIVAX™ PE34
process and VARIVAX™ (2016 commercial product) will be packaged identically so that 
the blind is maintained. The subject, the investigator and Sponsor personnel or delegate(s) 
who are involved in the vaccine administration or clinical evaluation of the subjects are 
unaware of the group assignments.
See Section 7.1.4.2, Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, should such action be warranted.
Randomization or Vaccine Allocation
5.3
Vaccine
randomization will occur centrally using an interactive voice response 
system/integrated web response system (IVRS/IWRS).  There are 2 vaccination groups.  
Subjects will be assigned randomly in a 1:1 ratio to VARIVAX™ PE34 process (Group 1) or 
VARIVAX™ (2016 commercial product) (Group 2), respectively.
Stratification
5.4
No stratification based on age, sex or other characteristics will be used in this trial.
Concomitant Medications/Vaccinations (Allowed and Prohibited)
5.5
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specifically prohibited during the trial, discontinuation from trial therapy or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director.  The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the subject's primary physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the Sponsor and the subject’s legally acceptable representative.
All medications administered from 30 days before each trial vaccination through 42 days 
after each trial vaccination should be recorded on the appropriate eCRF. Subjects should not 
have received any previous measles-, mumps-, rubella-, or VZV-containing vaccines, either 
alone or in any combination, or any such vaccines outside of trial protocol for the duration of 
the trial.
 
 
04S63N
 
 
055D6R

Product:  V210 
24
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Subjects should not have received salicylates (e.g., aspirin or any aspirin-containing 
products) during the 14 days before Vaccination 1, and should not receive these products 
until after 42 days after Vaccination 2, because the use of salicylates in children with 
varicella has been associated with Reye syndrome. Subjects must not have received any 
immunoglobulin, a blood transfusion, or blood-derived products (does not include autologous 
blood/blood products) for at least 5 months (150 days) before vaccination and should not 
receive these products while enrolled in this trial, unless there is a medical necessity 
warranting their use.
Use of immunosuppressive therapies is reason for exclusion, with the following exceptions:
1. Use of topical, ophthalmic, and inhaled steroids is permitted.
2. Use of systemic immunomodulatory steroids must meet the following criteria:

Subjects should not receive any dose of systemic immunomodulatory steroids within
7 days before or after each vaccination.

Subjects should not receive systemic immunomodulatory steroids (no more than the 
equivalent of 2 mg/kg total daily dose of prednisone or equivalent or >20mg/day of 
prednisone or equivalent for subjects weighing >10 kg) for more than 7 consecutive 
days from the time of trial start through the end of the 42-day safety follow-up period 
Postvaccination 2.
If 
higher 
doses 
of 
systemic 
immunomodulatory
steroids 
or 
other 
systemic 
immunosuppressive agents are administered after trial entry but before Vaccination 2, or if 
the subject otherwise develops an immunosuppressive condition in this interval, then the 
second dose of trial vaccines should be discontinued.
It is preferable that other vaccines routinely administered to children who are between
12 months to 23 months of age be given outside of the trial period so as not to confound the 
results from this trial.  These vaccines will not be provided by the Sponsor or Sponsor
designee.  If necessary, enrollment in the trial can be deferred if a medically important 
vaccine needs to be administered; however, the subject would only be permitted to continue 
with a delayed vaccination if the visit can be performed within the allowed window.  A full 
15 days must elapse between the receipt of inactivated nontrial vaccines and enrollment into 
the trial. A full 31 days must elapse between the receipt of live nontrial vaccines (e.g., 
yellow fever) and enrollment into the trial.
If medically necessary, both licensed inactivated and live nontrial vaccines may be 
administered in the interval between Visit 2 and Visit 3.  As specified in Section 5.1.3, a 
minimum of 43 days should elapse between Visit 1 (when the first dose of trial vaccine is 
administered) and receipt of the inactivated or live nontrial vaccine.  In addition:

If a licensed, inactivated (nonlive) vaccine (e.g., IPV, DTaP, Hib) is given between 
Visits 2 and 3, the second dose of trial vaccine must not be given until at least 15 days 
have elapsed.

If a licensed live vaccine is given between Visits 2 and 3, the second dose of trial
vaccine must not be given until at least 31 days have elapsed.
 
 
04S63N
 
 
055D6R

Product:  V210 
25
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
After the successful completion of trial procedures at Visit 4 (Week 19 [Days 133-147 
Postvaccination 1]), both inactivated and live nontrial vaccines may be administered.
Rescue Medications & Supportive Care
5.6
No rescue or supportive medications are specified to be used in this trial.
See Section 7.1.2.1.3, General Precautions for Administration, regarding administration of
epinephrine in the event of an anaphylactic reaction.
Diet/Activity/Other Considerations
5.7
No special restrictions on diet or activity apply.
Subject Withdrawal/Discontinuation Criteria
5.8
Discontinuation of Vaccination
5.8.1
Discontinuation of vaccination does not represent withdrawal from the trial.
As certain data on clinical events beyond vaccination discontinuation may be important to 
the study, they must be collected through the subject’s last scheduled follow-up, even if the 
subject has discontinued vaccination.  Therefore, all subjects who discontinue trial 
vaccination prior to completion of the vaccination period will still continue to participate in 
the trial as specified in Section 6.0 (Trial Flow Chart) and Section 7.1.5.3 (Discontinued 
Subjects Continuing to be Monitored in the Trial) unless consent is withdrawn. For subjects 
who will not receive Vaccination 2, all tasks except vaccination and eVRC should be 
completed.
Subjects may discontinue vaccination at any time for any reason or be dropped from 
vaccination at the discretion of the investigator should any untoward effect occur.  In 
addition, a subject may be discontinued from vaccination by the investigator or the Sponsor 
if vaccination is inappropriate, the trial plan is violated, or for administrative and/or other 
safety reasons.  Specific details regarding procedures to be performed at vaccination
discontinuation are provided in Section 7.1.4 – Other Procedures.
A subject must be discontinued from vaccination but continue to be monitored in the trial for 
any of the following reasons:
○
The subject or subject’s legally acceptable representative requests to discontinue 
vaccination.
o
The subject has a medical condition or personal circumstance that, in the opinion 
of the investigator and/or Sponsor, places the subject at unnecessary risk through 
continued participation in the trial or does not allow the subject to adhere to the 
requirements of the protocol.
o
The subject meets any of the criteria in Section 5.1.3.
o
Treatment unblinding.
 
 
04S63N
 
 
055D6R

Product:  V210 
26
Protocol/Amendment No.:  A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
For subjects who are discontinued from vaccination but continue to be monitored in the trial, 
all visits and procedures, as outlined in the trial flowchart, except vaccination and eVRC 
should be completed.
Discontinuation from vaccination is “permanent.” Once a subject is discontinued, he/she 
shall not be allowed to restart vaccination.
Withdrawal from the Trial
5.8.2
A subject must be withdrawn from the trial if the subject’s legally acceptable representative 
withdraws consent from the trial.
If a subject withdraws from the trial, they will no longer receive vaccination or be followed 
at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should a subject repeatedly fail to return for 
scheduled visits and/or if the study site is unable to contact the subject, as well as specific 
details regarding withdrawal from Future Biomedical Research are outlined in Section 7.1.4 
– Other Procedures.
Subject Replacement Strategy
5.9
A subject who withdraws from the trial will not be replaced.
Beginning and End of the Trial
5.10
The overall trial begins when written informed consent is provided for the first subject.  The 
overall trial ends when the last subject completes the last study-related phone-call or visit,
withdraws from the trial or is lost to follow-up (i.e. the subject is unable to be contacted by 
the investigator).  For purposes of analysis and reporting, the overall study ends when the 
Sponsor receives the last serology assay result.
Clinical Criteria for Early Trial Termination
5.11
There are no pre-specified criteria for terminating the trial early.
 
 
04S63N
 
 
055D6R

Product:  V210 
27
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
6.0 TRIAL FLOW CHART
Visit Number:
1
2
3
4
5
Visit Title:
Randomization/
Vaccination 1
Vaccination 1 
Follow-upa
Vaccination 2b
Vaccination 2 
Follow-upa,c
Phone Callc
Trial Timing:
Week 1
Week 6
Week 13
Week 19
Month 9
Trial Days:
Day 1
Days 43-57
Days 91-105
Days 133-147
Days 271-285
Administrative Procedures
Obtain informed consent
X
Obtain informed consent for future biomedical researchd
X
Assign screening number
X
Distribute subject identification card
X
Review inclusion/exclusion criteria
X
Review deferment/exclusion criteria (before Vaccination 2)
X
Review medical history
X
Review concomitant medication and nontrial vaccines
X
X
X
X
Assign treatment allocation/randomization using IVRS/IWRS
X
X
Laboratory Procedures/Assessments
Obtain buccal swabs (DNA) for Future Biomedical Researchd
X
Obtain blood sample for immunogenicity testinge
X
X
Clinical Procedures/Assessments
Take temperature (oral or equivalent)f
X
X
Administer VARIVAX™(left arm [or left anterolateral thigh])f
Group 1: VARIVAX™ PE34 process
Group 2: VARIVAX™ (2016 commercial product)
X
X
Administer M-M-R™ II (right arm [or right anterolateral thigh])f
X
X
Observe subject for anaphylaxis or other allergic reaction (at least 30 minutes)
X
X
Distribute eVRC/review instructions with subject/legally acceptable representativeg
X
X
Review eVRC reports with legally acceptable representativeh
X
X
Educate subject/legally acceptable representative on serious adverse events definition 
and reporting
X
X
X
X
Review adverse events and serious adverse eventsi
X
X
X
Collect eVRC device
X
Active assessment (using scripted safety questions) for occurrence of possible serious 
adverse events and medically attended adverse events
X
a.
Visit 2 and Visit 4 should be performed no sooner than 42 days after the previous vaccination.
b.
The subject would only be permitted to continue with a delayed vaccination if the visit can be performed within the 14-day window.
c.
For subjects who will not receive Vaccination 2, all tasks except vaccination and electronic Vaccination Report Card should be completed.
d.
Informed consent for optional future biomedical research samples must be obtained to collect the DNA sample.  
 
 
04S63N
 
 
055D6R

Product:  V210 
28
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Visit Number:
1
2
3
4
5
Visit Title:
Randomization/
Vaccination 1
Vaccination 1 
Follow-upa
Vaccination 2b
Vaccination 2 
Follow-upa,c
Phone Callc
Trial Timing:
Week 1
Week 6
Week 13
Week 19
Month 9
Trial Days:
Day 1
Days 43-57
Days 91-105
Days 133-147
Days 271-285
e.
A 3-mL blood sample will be taken on Day 1, immediately before vaccination with VARIVAX™and at Week 6 (43-57 days after Day 1 vaccination with VARIVAX™. The 
Visit 1 (Day 1) immunogenicity blood sample is mandatory for enrollment. Leftover main trial serum will be stored for future biomedical research if the parent/legally 
acceptable representative consents to future biomedical research.
f.
Before vaccination with trial vaccine, review all eligibility criteria, including subject’s temperature.  If the subject has a fever (defined as an oral temperature of 102.2°F 
(39.0C) or equivalent, the subject should not receive trial vaccine and the vaccination visit should be rescheduled until >72 hours after resolution of the febrile illness.  If the 
subject’s axillary temperature is ≥98.6°F (37.0°C), the parent/legally acceptable representative will be requested to further measure and record the subject’s rectal temperature 
in the eVRC. Parents/legally acceptable representatives should only record axillary temperatures and rectal temperatures as indicated. Oral temperatures and otic temperatures 
should not be recorded by parents/legally acceptable representatives.
g.
The eVRC device is dispensed at Visit 1.  Only instructions are reviewed at Visit 3.
h.
The eVRC (Section 7.1.1.9) is required to be completed for a full 42 days after each vaccination.  The eVRC device will be distributed at Visit 1 and returned to the site at 
Visit 4.  At Visit 3, the subject or parent/legally acceptable representative must be reminded to return with the eVRC device at Visit 4.
i.
The development of varicella-like, HZ-like, measles-like and rubella-like rashes and mumps-like symptoms through 42 days after vaccination will be recorded on the eVRC.  
The subject’s parent/legally acceptable representative will be instructed to contact trial personnel immediately if a varicella- or HZ-like rash develops.  Subjects are required 
to be seen at the clinic within 72 hours of the rash presentation.  Trial personnel will review the completed eVRC reports to identify any unreported occurrences of these 
specific conditions.
 
 
04S63N
 
 
055D6R

Product:  V210 
29
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
7.0 TRIAL PROCEDURES
Trial Procedures
7.1
The Trial Flow Chart - Section 6.0 summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary to 
perform these procedures at unscheduled time points if deemed clinically necessary by the 
investigator.
Furthermore, additional evaluations/testing may be deemed necessary by the investigator and 
or the Sponsor for reasons related to subject safety. In some cases, such evaluation/testing 
may be potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject’s legally 
acceptable representative.  In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
Administrative Procedures
7.1.1
Informed Consent
7.1.1.1
The investigator or qualified designee must obtain documented consent from each potential 
subject’s legally acceptable representative prior to participating in a clinical trial or Future 
Biomedical Research. If there are changes to the subject’s status during the trial (e.g., health 
or age of majority requirements), the investigator or qualified designee must ensure the 
appropriate consent is in place. 
7.1.1.1.1 General Informed Consent
Consent must be documented by the subject’s legally acceptable representative’s dated 
signature on a consent form along with the dated signature of the person conducting the 
consent discussion. 
A copy of the signed and dated consent form should be given to the subject’s legally 
acceptable representative before that subject’s participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject’s legally acceptable representative must 
receive the IRB/ERC’s approval/favorable opinion in advance of use.  The subject’s legally 
acceptable representative should be informed in a timely manner if new information becomes 
available that may be relevant to willingness for the subject to continue participation in the 
trial.  The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the subject’s legally 
acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
 
 
04S63N
 
 
055D6R

Product:  V210 
30
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements.
7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research consent 
to the subject’s legally acceptable representative, answer all of his/her questions, and obtain 
written informed consent before performing any procedure related to the Future Biomedical 
Research sub-trial.  A copy of the informed consent will be given to the subject’s legally 
acceptable representative.
Inclusion/Exclusion Criteria
7.1.1.2
All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
Subject Identification Card
7.1.1.3
The legally acceptable representative for each subject will be given a Subject Identification 
Card identifying the subject as a participant in a research trial. The card will contain trial site 
contact information (including direct telephone numbers) to be utilized in the event of an 
emergency. The investigator or qualified designee will provide the legally acceptable 
representative for each subject with the a Subject Identification Card immediately after 
written informed consent is provided. At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization number to the Subject Identification Card.
The subject identification card also contains contact information for the emergency 
unblinding call center so that a health care provider can obtain information about trial 
medication/vaccination in emergency situations where the investigator is not available.
Medical History
7.1.1.4
The eligibility of a subject will be assessed, and a medical history will be obtained to ensure 
that the subject satisfies the inclusion and exclusion criteria of the trial.  No physical 
examination is required for entry into the trial.
Prior and Concomitant Medications Review
7.1.1.5
7.1.1.5.1 Prior Medications
Before trial vaccination, the investigator or qualified designee will review and record prior 
medications and vaccinations received by the subject within the specified time periods.  
Prohibited prior medications and vaccinations are listed in the Exclusion Criteria in 
Section 5.1.3.
 
 
04S63N
 
 
055D6R

Product:  V210 
31
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial. Prohibited concomitant medications are listed in Section 5.5.
Assignment of Screening Number
7.1.1.6
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be assigned only one screening number.  Screening numbers must not be re-used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Assignment of Treatment/Randomization Number
7.1.1.7
All eligible subjects will be randomly allocated and will receive a treatment/randomization 
number.  The treatment/randomization number identifies the subject for all procedures 
occurring after randomization.  Once a treatment/randomization number is assigned to a 
subject, it can never be re-assigned to another subject.
A single subject cannot be assigned more than 1 treatment/randomization number.
Trial Compliance (Medication/Diet/Activity)
7.1.1.8
Trial vaccine will be administered by the investigator or qualified designee.  No special 
restrictions on diet or activity apply.
Distribution of Electronic Vaccination Report Card (eVRC)
7.1.1.9
The eVRC for this trial was developed to be provided electronically via a hand-held device.  
This item was structured as recommended in the final Food and Drug Administration (FDA) 
Patient Reported Outcome (PRO) Guidance.  The investigator or delegate will train the 
subject/parent or legally acceptable representative in the use of the eVRC device before
dispensing it to the subject/parent or legally acceptable representative at Visit 1 and will also 
review the instructions for using the eVRC device with the subject/parent or legally 
acceptable representative at Visit 3.  At Visit 3, the subject/parent or legally acceptable 
representative must be reminded to return with the eVRC device at Visit 4. 
Specific 
injection-site reactions will be solicited from Day 1 through Day 5 after vaccination with the 
trial vaccine (VARIVAX™ PE34 or VARIVAX™ 2016 commercial product) and M-M-R™ 
II.  Daily temperatures will be recorded on the eVRC from Day 1 through Day 42 after 
vaccination.
If the subject’s axillary temperature is ≥98.6°F (37.0°C), the parent/legally 
acceptable representative will be requested to further measure and record the subject’s rectal 
temperature in the eVRC.  The investigator or delegate will review the data captured on the 
eVRC with the subject at Visit 2 and Visit 4 and enter the data into the appropriate eCRF.
 
 
04S63N
 
 
055D6R

Product:  V210 
32
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Clinical Procedures/Assessments
7.1.2
Vaccine Administration
7.1.2.1
7.1.2.1.1 Preparation of Trial Vaccine
The designated study site personnel will reconstitute the trial vaccine using only the diluent 
provided by the Sponsor. The diluent for the vaccine is sterile distilled water and contains no 
preservatives or other substances that might inactivate the vaccine. 
To reconstitute the 
vaccine, first withdraw the entire contents of the diluent vial into a sterile syringe.  Inject all 
of the diluent in the syringe into the vial of lyophilized vaccine and gently swirl to mix 
thoroughly. Withdraw and administer the entire contents (~0.5 mL) of the vial.
CAUTION: 
•
Sterile syringes should be free of preservatives, antiseptics, and detergents as these 
substances may inactivate the vaccine virus.
•
Protect the vaccine from light at all times since such exposure may inactivate the 
vaccine virus. It is recommended that the vaccine be administered immediately after 
reconstitution to minimize loss of potency.
•
Do not freeze reconstituted vaccine.
7.1.2.1.2 Administration of Trial Vaccines
VARIVAX™ should be administered subcutaneously in the outer aspect of the upper left 
arm (deltoid) or left anterolateral thigh. All vaccinations and location of injection should
be recorded on the appropriate eCRF. A 25-gauge, 5/8" needle is recommended.  Subjects 
should be observed for anaphylaxis or other reactions for at least 30 minutes after
vaccination.
M-M-R™ II should be administered subcutaneously in the outer aspect of the upper right 
arm (deltoid) or right anterolateral thigh. All vaccinations and location of injection 
should be recorded on the appropriate eCRF. A 25-gauge, 5/8" needle is recommended.  
Subjects should be observed for anaphylaxis or other reactions for at least 30 minutes after
vaccination.
Details of the vaccination should be documented, including the time the vaccine vial is 
removed from the refrigerator, the time of reconstitution, the time of administration of the 
vaccine, the site and route of administration, and the dose volume administered. If not used 
within 30 minutes of removal from the refrigerator, a new vial must be reconstituted. Do 
not freeze reconstituted vaccine. Vials that are reconstituted and not used must be recorded 
on the vaccine accountability form for this trial.
 
 
04S63N
 
 
055D6R

Product:  V210 
33
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
7.1.2.1.3 General Precaution for Administration of Vaccine
Adequate treatment provision, including epinephrine, should be available for immediate use 
should an anaphylactic reaction occur. Subjects should be observed for anaphylaxis or other 
reactions for at least 30 minutes after vaccination.
A separate sterile syringe and needle or sterile disposable unit should be used for the 
administration of vaccine to each subject to prevent transmission of infectious agents from 
one person to another. Needles should not be recapped. Safe disposal procedures should be 
followed.
7.1.2.1.4 Temperature Procedures
The parent/legally acceptable representative for each subject will be instructed to measure 
and record in the eVRC the subject’s axillary temperature 4 to 6 hours postvaccination and 
then daily, preferably at the same time each day, through 42 days after each vaccination.  If 
the subject’s axillary temperature is ≥98.6°F (37.0°C), the parent/legally acceptable 
representative will be requested to further measure and record the subject’s rectal 
temperature in the eVRC.  Trial personnel should advise the parent/legally acceptable 
representative on the proper manner in which to measure axillary and rectal temperatures to 
ensure that accurate measurements are obtained.  The parents/legally acceptable 
representative should not record oral or otic temperatures.
7.1.2.1.5 Clinical Follow-up
Subjects will be followed for adverse events through 42 days after each vaccination. Specific 
injection-site reactions will be solicited from Day 1 through Day 5 after vaccination with the 
trial vaccine (VARIVAX™ PE34 or VARIVAX™ 2016 commercial product) and M-M-R™ 
II. Daily temperatures will be recorded on an eVRC from Day 1 through Day 42 after
vaccination. Regardless of severity or causality, all unsolicited injection-site reactions; and 
all systemic adverse events, including varicella-, zoster-, measles-, rubella-like rashes and 
mumps-like symptoms, will be recorded on an eVRC for Day 1 through Day 42 after
vaccination. Serious adverse events, including death, will be reported from Day 1 after the
first dose of trial vaccine through Day 180 after the second dose of trial vaccine.  Medically 
attended adverse events will be reported from Day 133 through Day 271.  During the phone 
call at Day 271 (Day 180 Postvaccination 2), a scripted questionnaire will be used to 
determine if any serious adverse events or medically attended adverse events have occurred 
for each subject since completing the 42-day safety follow-up period Postvaccination 2.
The parent/legally acceptable representative of each subject will record the safety data on the 
eVRC and return the eVRC to the trial site at Visit 4. Trial personnel will review the eVRC 
for completeness, accuracy, and clarity. All information will be accurately recorded on the 
appropriate eCRFs.
 
 
04S63N
 
 
055D6R

Product:  V210 
34
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Laboratory Procedures/Assessments
7.1.3
Details regarding specific laboratory procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pretrial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected by visit and by sample type per subject, can be found in Section 12.3.
Laboratory Immunogenicity Evaluations
7.1.3.1
7.1.3.1.1 Blood Sample Collection for Antibody Measurement
A 3-mL blood sample will be obtained from all subjects just before vaccination at Visit 1 
(Day 1) and at Visit 2 (Day 43 [+14 days] Postvaccination 1). For all subjects at Visit 1 
(Day 1), it is mandatory to collect a blood sample before a subject is randomized.  Subjects 
must not be randomized into the trial if a blood sample cannot be obtained. Serum should be 
collected, processed, and shipped according to the instructions provided in the laboratory 
manual. All serum specimens will be sent to PPD Vaccines and Biologics, LLC, Richmond, 
VA, USA, on dry ice.
7.1.3.1.2 Detection of IgG Antibody to VZV (gpELISA)
The purpose of the gpELISA is to detect IgG antibody to VZV before and after vaccination 
with VZV-containing vaccine(s). This is the primary assay used to evaluate the serological 
response to VZV-containing vaccine(s). 
This method detects antibodies to VZV 
glycoprotein (gp), which has been purified from MRC-5 cells infected with the KMcC strain 
of VZV by lectin-affinity chromatography. The reactivity of the sera to the gp antigens from 
uninfected MRC-5 cells (denoted as tissue culture control [TCC] wells]) is subtracted from 
the reactivity of the sera to the gp antigens purified from VZV-infected MRC-5 cells. The 
assay and the purification of the VZV gp from VZV-infected cells are described [13] [14] 
[15]. 
Serum sample titers as determined by gpELISA are shown to correlate with 
neutralizing antibody titers [16].
For the gpELISA, VZV gp or TCC antigen is adsorbed to polystyrene microtiter wells and 
used as the solid phase antigen. Experimental, control, and standard curve sera are incubated 
in VZV gp-coated and TCC-coated wells (2 wells for each antigen). For each serum sample, 
a delta optical density (DOD) is calculated as the difference between the average optical 
density (OD) of the 2 VZV antigen wells and the average OD of the 2 TCC wells. 
Quantitation is obtained by comparison of sample DOD with a standard curve. Results for 
the assay are reported as concentration of antibody in gpELISA units/mL.
The negative control used for this assay is an individual human serum at a dilution of 1:50, 
found to be negative for anti-VZV. The high-positive control is a VZV antibody-positive 
serum, diluted 1:500, which gives a response in the assay at the upper end of the standard 
curve. The low-positive control is a VZV antibody-positive serum diluted 1:50, which gives 
a response in the assay at the lower end of the standard curve. A VZV antibody-positive 
individual human serum was used to generate a standard curve.
 
 
04S63N
 
 
055D6R

Product:  V210 
35
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Future Biomedical Research Samples
7.1.3.2
The following specimens are to be obtained as part of Future Biomedical Research:

DNA for future research

Leftover main trial serum from immunogenicity testing stored for future research
Other Procedures
7.1.4
Withdrawal/Discontinuation
7.1.4.1
Subjects who discontinue vaccination prior to completion of the vaccination regimen should 
be encouraged to continue to be followed for all remaining study visits.
When a subject discontinues/withdraws from participation in the trial, all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  Any 
adverse events which are present at the time of discontinuation/withdrawal should be 
followed in accordance with the safety requirements outlined in Section 7.2 - Assessing and 
Recording Adverse Events.
7.1.4.1.1 Withdrawal From Future Biomedical Research
A subject’s consent for Future Biomedical Research may be withdrawn by the subject’s 
legally acceptable representative.  A subject’s consent may be withdrawn at any time by 
contacting the principal investigator for the main trial.  If medical records for the main trial 
are still available, the investigator will contact the Sponsor using the designated mailbox 
(clinical.specimen.management@merck.com).  Subsequently, the subject's consent for Future 
Biomedical Research will be withdrawn.  A letter will be sent from the Sponsor to the 
investigator confirming the withdrawal. It is the responsibility of the investigator to inform 
the subject of completion of withdrawal.  Any analyses in progress at the time of request for 
withdrawal or already performed prior to the request being received by the Sponsor will 
continue to be used as part of the overall research trial data and results.  No new analyses 
would be generated after the request is received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory authorities to retain the main trial records) or 
the specimens have been completely anonymized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen withdrawal cannot be processed.
 
 
04S63N
 
 
055D6R

Product:  V210 
36
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
7.1.4.1.2 Lost to Follow-up
If a subject fails to return to the clinic for a required trial visit and/or if the site is unable to 
contact the parent/legally acceptable representative, the following procedures are to be 
performed:

The site must attempt to contact the parent/legally acceptable representative and 
reschedule the missed visit.  If the parent/legally acceptable representative is 
contacted, the parent/legally acceptable representative should be counseled on the 
importance of maintaining the protocol-specified visit schedule.

The investigator or designee must make every effort to regain contact with the 
parent/legally acceptable representative at each missed visit (e.g., phone calls 
and/or a certified letter to the last known mailing address of the parent/legally 
acceptable representative or local equivalent methods). These contact attempts 
should be documented in the subject’s medical record.

Note:  A subject is not considered lost to follow up until the last scheduled visit 
for the individual subject.  The amount of missing data for the subject will be 
managed via the pre-specified data handling and analysis guidelines.
Subject Blinding/Unblinding
7.1.4.2
When the investigator or delegate needs to identify the drug used by a subject and the dosage 
administered in case of emergency e.g., the occurrence of serious adverse events, he/she will 
contact the emergency unblinding call center by telephone and make a request for emergency 
unblinding.  As requested by the investigator or delegate the emergency unblinding call 
center will provide the information to him/her promptly and report unblinding to the Sponsor.  
Prior to contacting the emergency unblinding call center to request unblinding of a subject’s 
treatment assignment, the investigator or delegate must enter the intensity of the adverse 
events observed, the relation to study drug, the reason thereof, etc., in the medical chart etc.
Subjects whose treatment assignment has been unblinded by the investigator/delegate and/or 
non-study treating physician must be discontinued from study drug, but should continue to be 
monitored in the trial.
Additionally, the investigator must go into the IVRS system and perform the unblind in the 
IVRS system to update drug disposition.  In the event that the emergency unblinding call 
center is not available for a given site in this trial, IVRS/IWRS should be used for emergency 
unblinding in the event that this is required for subject safety.
Treatment/Vaccine identification information is to be unmasked ONLY if necessary for the 
welfare of the subject.  Every effort should be made not to unblind the subject unless 
necessary. 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible. Only the principal investigator or 
 
 
04S63N
 
 
055D6R

Product:  V210 
37
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
delegate and the respective subject’s code should be unblinded. Other trial site personnel and 
Sponsor personnel directly associated with the conduct of the trial should not be unblinded.
At the end of the trial, random code/disclosure envelopes or lists and unblinding logs are to 
be returned to the Sponsor or designee.
Calibration of Critical Equipment
7.1.4.3
The investigator or qualified designee has the responsibility to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be 
suitably calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:

2°C to 8°C refrigerator with temperature-monitoring device

–20°C freezer with temperature-monitoring device

Centrifuge
Visit Requirements
7.1.5
Visit requirements are outlined in Section 6.0 - Trial Flow Chart. Specific procedure-related 
details are provided above in Section 7.1 - Trial Procedures.
Screening
7.1.5.1
Screening procedures will be performed at Visit 1. A separate screening visit is not required.
Vaccination Visits
7.1.5.2
See Section 6.0 for details.
Post-trial (Visit 4: Follow-up Visit, and Visit 5: Follow-up Phone Call)
7.1.5.3
Visit 4 Follow-up Visit: Subjects will be required to return to the clinic 6 to 8 weeks after 
Vaccination 2.
Visit 5 Follow-up Phone Call: In addition, 6 months after Vaccination 2, a follow-up phone 
call will be made to determine if any serious adverse events or medically attended adverse 
events have occurred since Visit 4.
Assessing and Recording Adverse Events
7.2
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory finding, for example), 
 
 
04S63N
 
 
055D6R

Product:  V210 
38
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
symptom, or disease temporally associated with the use of a medicinal product or protocol-
specified procedure, whether or not considered related to the medicinal product or protocol-
specified procedure.  Any worsening (i.e., any clinically significant adverse change in 
frequency and/or intensity) of a preexisting condition that is temporally associated with the 
use of the Sponsor’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantly in 
frequency or severity from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typical crying in infants and 
children and onset of menses or menopause occurring at a physiologically appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol-specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by or 
distributed by the Sponsor for human use.
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the consent form is signed but before 
allocation/randomization must be reported by the investigator if they cause the subject to be 
excluded from the trial, or are the result of a protocol-specified intervention, including but 
not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a 
procedure. From the time of allocation/randomization through 14 days (42 days for live 
attenuated vaccines) following the first vaccination(s) and from the time of any subsequent 
vaccination(s) through 14 days (42 days for live attenuated vaccines) thereafter, all adverse 
events must be reported by the investigator. Such events will be recorded at each 
examination on the Adverse Event case report forms/worksheets. The reporting timeframe 
for adverse events meeting any serious criteria is described in Section 7.2.2.1. The 
investigator will make every attempt to follow all subjects with non-serious adverse events 
for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC) data 
entry guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 
7.2.1
Sponsor
In this trial, an overdose is any dose higher than 1 dose of trial vaccine administered within 
24 hours.
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious 
criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory results, the overdose is 
 
 
04S63N
 
 
055D6R

Product:  V210 
39
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
reported as a non-serious adverse event using the terminology “accidental or intentional 
overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported by the 
investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic 
reporting procedures can be found in the EDC data entry guidelines. Paper reporting 
procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events to the Sponsor
7.2.2
Serious Adverse Events
7.2.2.1
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●
Results in death;
●
Is life threatening;
●
Results in persistent or significant disability/incapacity;
●
Results in or prolongs an existing inpatient hospitalization;
●
Is a congenital anomaly/birth defect;
●
Is an other important medical event.
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. 
●
Is a cancer;
●
Is associated with an overdose.
Refer to Table 2 for additional details regarding each of the above criteria.  
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any cause, that occurs to any subject must be reported within 24 hours 
to the Sponsor if it causes the subject to be excluded from the trial, or is the result of a 
protocol-specified intervention, including but not limited to washout or discontinuation of 
usual therapy, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/randomization through 6 months 
(~180 days) following the second vaccination, any serious adverse event, or follow up to a 
serious adverse event, including death due to any cause, whether or not related to the 
Sponsor's product, must be reported within 24 hours to the Sponsor either by electronic 
media or paper. Electronic reporting procedures can be found in the EDC data entry 
guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
 
 
04S63N
 
 
055D6R

Product:  V210 
40
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Additionally, any serious adverse event brought to the attention of an investigator who is a 
qualified physician at any time outside of the time period specified in the previous paragraph 
also must be reported immediately to the Sponsor if the event is either:
1. A death that occurs prior to the subject completing the trial, but outside the time period 
specified in the previous paragraph.
or
2. A serious adverse event that is considered by an investigator who is a qualified physician 
to be vaccine related.
All subjects with serious adverse events must be followed up for outcome.
Events of Clinical Interest
7.2.2.2
Selected non-serious and serious adverse events are also known as Events of Clinical Interest 
(ECI) and must be reported to the Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, 
or is the result of a protocol-specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/randomization through 14 days 
following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by electronic 
media or paper.  Electronic reporting procedures can be found in the EDC data entry 
guidelines.  Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Events of clinical interest for this trial include:

No ECIs are being collected for this trial.
Evaluating Adverse Events
7.2.3
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 2. The investigator’s assessment of causality is required for 
each adverse event.  Refer to Table 2 for instructions in evaluating adverse events.
 
 
04S63N
 
 
055D6R

Product:  V210 
41
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Table 2
Evaluating Adverse Events
Maximum
Mild
awareness of sign or symptom, but easily tolerated (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity
Moderate
discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe
incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities) 
Injection site redness or swelling from the day of vaccination through Day 5 post-vaccination will be evaluated by maximum size.
Seriousness
A serious adverse event (AE) is any adverse event occurring at any dose that:
†Results in death; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre-existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in the 
patient’s medical history.); or
†Is a congenital anomaly/birth defect  (in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per ICH definition, is reportable to the Sponsor within 24 hours to meet certain local requirements; or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is
reportable to the Sponsor within 24 hours to meet certain local requirements.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse event when, 
based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration
Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken 
Did the adverse event cause the test vaccine to be discontinued?
Relationship 
to test vaccine 
Did the test vaccine cause the adverse event? The determination of the likelihood that the test vaccine caused the adverse event will be provided by an investigator who 
is a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a 
medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The criteria below are intended 
as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test vaccine and the adverse event based upon the available 
information.  
The following components are to be used to assess the relationship between the test vaccine and the AE; the greater the correlation with the components and their 
respective elements (in number and/or intensity), the more likely the test vaccine caused the adverse event:
Exposure
Is there evidence that the subject was actually exposed to the test vaccine such as:  reliable history, acceptable compliance assessment 
(e.g., diary), seroconversion or identification of vaccine virus in bodily specimen?
Time Course
Did 
the 
AE 
follow 
in 
a 
reasonable 
temporal 
sequence 
from 
administration 
of 
the 
test 
vaccine? 
Is the time of onset of the AE compatible with a vaccine-induced effect?
Likely Cause
Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or
environmental factors
 
 
04S63N
 
 
055D6R

Product:  V210 
42
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Relationship
The following components are to be used to assess the relationship between the test vaccine and the AE:  (continued)
to test vaccine 
Dechallenge
(not applicable for vaccines)
(continued) 
Rechallenge
Was the subject reexposed to the test vaccine in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single-dose 
vaccine trial.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE 
BEEN CAUSED BY THE TEST VACCINE, OR IF REEXPOSURE TO THE TEST VACCINE POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR
CLINICAL DIRECTOR AND THE INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE.
Consistency with Trial 
Vaccine Profile
Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the test vaccine or vaccine class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.  
Record one of the following:
Use the following criteria as guidance (not all criteria must be present to be indicative of a vaccine relationship).
Yes, there is a reasonable possibility of 
vaccine relationship.
There is evidence of exposure to the test vaccine.  The temporal sequence of the AE onset relative to the administration of the test vaccine 
is reasonable.  The AE is more likely explained by the test vaccine than by another cause.
No, there is not a reasonable possibility of 
vaccine relationship
Subject did not receive the test vaccine OR temporal sequence of the AE onset relative to administration of the test vaccine is not 
reasonable OR the AE is more likely explained by another cause than the Sponsor’s product.  (Also entered for a subject with overdose 
without an associated AE.)
 
 
04S63N
 
 
055D6R

Product:  V210 
43
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Sponsor Responsibility for Reporting Adverse Events
7.2.4
All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations, i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice.
8.0 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the trial. If, after the 
trial has begun, but before any final database lock, changes made to primary and/or key 
secondary hypotheses, or the statistical methods related to those hypotheses, then the 
protocol will be amended (consistent with ICH Guideline E-9).  Changes to exploratory or 
other nonconfirmatory analyses made after the protocol has been finalized, but before final 
database lock, will be documented in a supplemental statistical analysis plan and referenced 
in the Clinical Study Report (CSR) for the trial.  Post hoc exploratory analyses will be clearly 
identified in the CSR.
Statistical Analysis Plan Summary
8.1
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Sections 8.2 through 8.11.
Study Design Overview
A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to 
Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™
Passage Extension 34 (PE34) Process Administered Concomitantly with 
M-M-R™II
Treatment Assignment
This is a double-blind trial with 2 vaccination groups. Subjects will be 
randomized to VARIVAX™PE34 process group and VARIVAX™(2016 
commercial product) group with the ratio 1:1.
Analysis Populations
Immunogenicity: Per-protocol (PP) and Full Analysis Set (FAS)
Safety: All Subjects as Treated (ASaT)
Primary Endpoint(s)
1.
The response rate, the proportion of subjects with VZV antibody 
titer 5 gpELISA units/mL 6 weeks Postvaccination 1 among 
subjects who were seronegative to VZV (titer <1.25 gpELISA 
units/mL) at baseline.
2.
The GMT of VZV antibodies in subjects at 6 weeks 
Postvaccination 1.
Key Secondary Endpoints
The seroconversion rate, the proportion of subjects with VZV antibody 
titer 1.25 gpELISA units/mL 6 weeks Postvaccination 1 among subjects 
who were seronegative to VZV (titer <1.25 gpELISA units/mL) at 
baseline.
Statistical Methods for Key 
Efficacy/Immunogenicity/ 
Pharmacokinetic Analyses
For the primary hypothesis 1, VARIVAX™PE34 process will be 
considered noninferior to VARIVAX™(2016 commercial product) if 
the lower bound of the 2-sided 95% CI of difference in response rates
(VARIVAX™PE34 process minus VARIVAX™[2016 commercial 
product]) excludes a decrease of 10 percentage points or more.  This 
analysis will be assessed using the Miettinen and Nurminen method [17].
For the primary hypothesis 2, VARIVAX™PE34 process will be 
considered noninferior to VARIVAX™(2016 commercial product) if 
the lower bound of the 2-sided 95% CI of the GMT ratio (VARIVAX™
PE34 process/VARIVAX™[2016 commercial product]) is >0.67.  This 
 
 
04S63N
 
 
055D6R

Product:  V210 
44
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
analysis will be assessed using 2-sample t test based on the 
log-transformed Postvaccination 1 antibody titers.
For the primary hypothesis 3, VARIVAX™PE34 process will be 
considered acceptable if the lower bound of the 95% CI for the response 
rate is above 76.0%.  This analysis will be assessed using the exact CI 
method for a single binomial proportion given in Collett [18].
Statistical Methods for Key 
Safety Analyses
The analysis of safety results will follow a tiered approach. The tiers 
differ with respect to the analyses that will be performed.
Tier 1 safety endpoints include the rate of fever (temperature ≥102.2°F 
[≥39.0°C] oral equivalent) from Days 1 to 42 after each vaccination; 
varicella-, zoster-, measles-, or rubella-like rashes or mumps-like 
symptoms, and injection-site rashes occurring within Days 1 to 42 after 
each vaccination; and solicited injection-site reactions (redness, swelling, 
pain/tenderness) within Days 1 to 5 after each vaccination. For Tier 1 
events, inferential testing for statistical significance with p values and 
95% CIs will be provided for between-group comparisons.
Any adverse experiences (specific terms as well as system organ class 
[SOC] terms) that are not pre-specified as endpoints of particular interest 
will be classified as belonging to Tier 2 or Tier 3. Tier 2 parameters will 
be assessed via point estimates with 95% CIs provided for between-
group comparisons; only point estimates by vaccination group are 
provided for Tier 3 safety parameters.  Analyses will be performed using 
the Miettinen and Nurminen method [17].
Interim Analyses
No interim analyses are planned for this trial.
Multiplicity
No multiplicity adjustment is planned as success of the trial requires 
success on both the noninferiority and acceptability hypotheses.
Sample Size and Power 
The planned sample size is ~600 subjects in total (~300 in each group). 
Assuming 80% evaluability, 90% Postvaccination 1 response rates, and a 
standard deviation of 1.2 for the log-transformed Postvaccination 1
antibody titers, this trial has 94.1% power for demonstrating 
noninferiority of the response rate, 95.8% power for demonstrating 
noninferiority of the GMT, and >99.9% power for demonstrating 
acceptability of the response rate at an overall 2-sided 5% α-level. The 
overall power for the primary immunogenicity hypotheses is estimated to 
be 90% (= 0.941 × 0.958 × >0.999).
Responsibility for Analyses/In-house Blinding
8.2
The statistical analysis of the data obtained from this trial will be the responsibility of the 
Clinical Biostatistics department of the Sponsor.
This trial will be conducted as a double-blind trial under in-house blinding procedures. The 
official final database will not be unblinded until medical/scientific review has been 
performed, protocol violators have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
trial treatment assignment.
 
 
04S63N
 
 
055D6R

Product:  V210 
45
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Hypotheses/Estimation
8.3
Objectives and hypotheses of the trial are stated in Section 3.0.
Analysis Endpoints
8.4
Immunogenicity and safety endpoints that will be evaluated for between-group differences 
are described below.
Immunogenicity Endpoints
8.4.1
The primary endpoints for VZV immunogenicity will be the antibody response rates and 
GMTs after the first dose of VARIVAX™ in subjects who were initially seronegative to 
VZV at baseline.
The response rate and GMT endpoints and the criteria for baseline seronegativity are defined 
below:

The response rate is the percentage of subjects with VZV antibody titer 
≥5 gpELISA units/mL 6 weeks Postvaccination 1
among subjects who were 
seronegative to VZV (titer <1.25 gpELISA units/mL) at baseline.

The postvaccination antibody GMTs 6 weeks Postvaccination 1.
In addition, the VZV seroconversion rate (defined as the proportion of subjects with baseline 
VZV titer <1.25 gpELISA units/mL and with postvaccination VZV titer ≥1.25 
gpELISA units/mL) will be summarized after the first dose.  For subjects who are initially 
seropositive (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the geometric mean 
fold rise (GMFR) and the percentage of subjects achieving ≥4-fold rise in antibody titer from 
baseline will be summarized after the first dose.
Safety Endpoints
8.4.2
Refer to Section 4.2.3.2 for the description of the safety measures in this trial.
The key safety endpoints evaluated as Tier 1 events are as follows: the rate of elevated 
temperature from Days 1 to 42 after each vaccination; varicella-, zoster-, measles-, or 
rubella-like rashes or mumps-like symptoms, and all injection-site rashes occurring within 
Days 1 to 42 after each vaccination, and all solicited injection-site reactions (redness, 
swelling, pain/tenderness) occurring within Days 1 to 5 after each vaccination.
Analysis Populations
8.5
Immunogenicity Analysis Populations
8.5.1
Per-protocol Population
8.5.1.1
The primary immunogenicity analyses will be based on the PP population.  The 
PP population consists of those subjects who are not considered as protocol violators.  
Violations include but are not limited to: failure to receive the full, scheduled doses (at least 
 
 
04S63N
 
 
055D6R

Product:  V210 
46
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
90 days between doses 1 and 2) of correct clinical material and lack of valid serology results 
available from 27 to 84 days following the first dose.  The day range for inclusion of 
postvaccination blood samples in the statistical analysis is wider than the visit window 
provided earlier in this protocol (+ 14 days for the 6-week serology testing), but is being used 
to be consistent with other studies evaluating VZV-containing vaccines.
In addition to meeting the PP population requirements, the primary analysis requires specific 
baseline criteria be met for VZV:  baseline VZV antibody titer <1.25 gpELISA units/mL.  
Additional immunogenicity summaries will be made for subjects who meet the PP population 
requirements but do not meet the baseline antibody requirement for VZV (e.g., a summary of 
Postvaccination 1 VZV immunogenicity in otherwise PP subjects who have a baseline VZV 
antibody titer ≥1.25 gpELISA units/mL; see Section 8.6.1.4 for details).
Supportive summaries at Postvaccination 1 will also be made for the PP population, as 
described in Section 8.6.1.4.
The final determination on protocol violations, and thereby the composition of the PP 
population, will be made before unblinding of the database and will be documented in a 
separate memo.
Full Analysis Set
8.5.1.2
A supportive summary and analysis for VZV immunogenicity will be based on the FAS.  The 
FAS population consists of all randomized subjects with a valid serology measurement, 
regardless of protocol violations.  Subjects will be included in the vaccination group to which 
they are randomized for the FAS population.  As a supportive analysis, the primary 
immunogenicity hypotheses will be evaluated on the FAS population in subjects meeting the 
VZV baseline antibody requirement to assess the robustness of the primary conclusions 
based on the PP population.
Safety Analysis Population
8.5.2
The ASaT population will be used for the analysis of safety data in this trial.  The ASaT 
population consists of all randomized/allocated subjects who received at least 1 dose of trial
treatment. 
Subjects will be included in the treatment group corresponding to the trial
treatment they actually received for the analysis of safety data using the ASaT population.  
For most subjects this will be the treatment group to which they are randomized.  Subjects 
who take incorrect trial treatment for the entire treatment period will be included in the 
treatment group corresponding to the trial treatment actually received (e.g., a subject who 
was randomized to Group 1 but received all vaccines according to the Group 2 schedule will 
be summarized with Group 2 subjects).   Subjects who receive a mixed regimen ( e.g., 
received VARIVAX™PE34 process at Visit 1, but received VARIVAX™ [2016 
commercial product] at Visit 3) will have their Postvaccination 1 safety data summarized 
with the group corresponding to the vaccine(s) received (for this example, with Group 1 
subjects), and subsequent safety data summarized separately from the Postvaccination 2 
summary for Group 1 and Group 2 subjects.
 
 
04S63N
 
 
055D6R

Product:  V210 
47
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Statistical Methods
8.6
To control the overall type I error rate at α = 0.025 (1-sided) and since success of the trial
requires success on 3 hypotheses (2 noninferiority and 1 acceptability), each individual 
hypothesis test will be evaluated at α = 0.025 (1-sided).
For the safety analyses, unless otherwise specified, all statistical tests will be conducted at 
α = 0.05 level (2-sided).
Statistical Methods for Immunogenicity Analysis
8.6.1
Noninferiority of Postvaccination 1
VZV Antibody Response (Primary 
8.6.1.1
Hypothesis 1)
For the primary hypothesis concerning the noninferiority of the Postvaccination 1 antibody 
response rate for recipients of VARIVAX™ PE34 process compared with VARIVAX™ 
(2016 commercial product), a 1-sided test for noninferiority in 2 binomial proportions will be 
performed at the α = 0.025 (1-sided) level.
The statistical hypothesis that will be evaluated is:
H0: p1 ‒ p2 ≤ -δ versus H1: p1 ‒ p2 >-δ,
where H0 is the null hypothesis, H1 is the alternative hypothesis, p1 and p2 are the true 
antibody response rates for the subjects in VARIVAX™ PE34 process and control 
groups, respectively, and δ is the pre-specified difference between the 2 proportions.  The 
pre-specified difference between the 2 proportions (δ) is 0.10 (10 percentage points).
This analysis will be unstratified and the test statistic, p value, and corresponding 95% CIs 
will be calculated using the Miettinen and Nurminen method, an unconditional, asymptotic 
method [17].  The response rate in subjects receiving a single dose of VARIVAX™ PE34 
process will be considered noninferior to the control group if the 1-sided p value for the 
associated noninferiority test is <0.025.  This criterion is equivalent to requiring the lower 
bound of the 2-sided 95% CI for the difference in rates (Group 1 minus Group 2) exclude a 
decrease of 10 percentage points or more.
This analysis will be conducted on the PP population and the FAS population; however, the 
PP population is the primary population for the assessment of the hypotheses.
Noninferiority of Postvaccination 1 VZV Antibody GMT (Primary Hypothesis 
8.6.1.2
2)
For the secondary hypothesis concerning the noninferiority of the Postvaccination 1 VZV 
antibody, GMT for recipients of VARIVAX™ PE34 process compared with VARIVAX™ 
(2016 commercial product), a 1-sided test for noninferiority in the VZV antibody GMT will 
be performed at the α = 0.025 level (1-sided).
 
 
04S63N
 
 
055D6R

Product:  V210 
48
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
The statistical hypothesis for the noninferiority of the antibody GMT is:
H0:  GMT1/GMT2 ≤0.67 versus H1:  GMT1/GMT2 >0.67,
where GMT1 is the GMT for recipients in Group 1 receiving VARIVAX™ PE34 process 
and GMT2 is the GMT for recipients in Group 2 receiving VARIVAX™ (2016 
commercial product).  A ratio of 0.67 corresponds to a 1.5-fold decrease in GMT in 
Group 1 compared with Group 2.  Rejecting the null hypothesis (H0) at the 1-sided 
α = 0.025 level corresponds to the lower bound of the 2-sided 95% CI for the GMT ratio 
(Group 1/Group 2) being >0.67.
The GMT ratio (VARIVAX™ PE34 process/VARIVAX™ [2016 commercial product])
along with a 2-sided 95% CI and p value will be determined at week 6 Postvaccination 1.  
Assuming normality of the log antibody titers, a 2-sided 95% CI for the difference in the 
means of the log titers (VARIVAX™ PE34 process minus VARIVAX™ [2016 commercial 
product]) will be constructed based on the t-distribution.  The CI of the GMT ratio 
(VARIVAX™ PE34 process/VARIVAX™ [2016 commercial product]) will then be 
provided by exponentiating the endpoints of the CI for the difference in log titers.
This analysis will be conducted on the PP and FAS populations; however, the PP population 
is the primary population for the assessment of the hypotheses.
Acceptability of Immune Response (Primary Hypothesis 3)
8.6.1.3
The primary hypotheses also involve whether or not subjects in Group 1 of VARIVAX™ 
PE34 process demonstrate an acceptable antibody response Postvaccination 1 to VZV 
(Hypothesis 3).  An acceptable antibody response to VZV is defined as a response rate that is 
at least 76.0%.  A hypothesis of H0: p≤p0 will be tested against the alternative H1: p>p0, 
where p is the antibody response rate after a single dose and p0 is the hypothesized rate to be 
ruled out (76.0% for VZV).  A 1-sided, 1-sample exact binomial test will be conducted at 
α = 0.025 significance level.  Rejection of the null hypothesis will lead to a conclusion of an 
acceptable antibody response to VZV.  This is equivalent to the lower bound of the 1-sample 
2-sided 95% CI being >76.0%.  The 1-sample 2-sided CIs will be computed using the exact 
CI method for a single binomial proportion given in Collett [18].
This analysis will be conducted on the PP population and the FAS population; however, the 
PP population is the primary population for the assessment of the hypotheses.
The strategy to address multiplicity issues with regard to multiple primary immunogenicity 
endpoints and primary immunogenicity hypotheses is described in Section 8.8 ‒ Multiplicity.
Secondary Summaries
8.6.1.4
In addition to the analysis described in Sections 8.6.1.1, 8.6.1.2, and 8.6.1.3 supporting the 
primary hypotheses, the following supportive summaries and figures will be presented for all 
subjects in the PP and FAS populations (where noted) with Postvaccination 1
immunogenicity data collected:
 
 
04S63N
 
 
055D6R

Product:  V210 
49
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential

The observed VZV antibody response rates (the percent of subjects with VZV titer ≥5 
gpELISA units/mL) will be summarized by vaccination group at Postvaccination 1, 
along with 2-sided 95% CIs.  The CIs will be computed using the exact CI method for 
a single binomial proportion given in Collett [18].  This will be computed on the 
PP population of subjects
(with baseline antibody titer restriction) and the 
FAS population (with baseline antibody titer restriction).

The observed VZV seroconversion rate (the percent of subjects with VZV titer 
≥1.25 gpELISA units/mL) will be summarized by vaccination group at 
Postvaccination 1, along with 2-sided 95% CIs.  The CIs will be computed using the 
exact method for a single binomial proportion given in Collett [18].  This will be 
computed on the PP population of subjects (with baseline antibody titer restriction) 
and the FAS population (with baseline antibody titer restriction).

The observed VZV GMTs will be summarized by vaccination group at 
Postvaccination 1, along with 2-sided 95% CIs.  The GMTs will be calculated by 
taking the natural log-transformation of the antibody titer, computing the arithmetic 
mean, and back-transforming.  The CIs for the GMTs will be based on the natural 
log-transformed titers and the t-distribution.  This will be computed on the 
PP population of subjects (with baseline antibody titer restrictions) and on the 
FAS population (with baseline antibody titer restrictions).

For subjects who are seropositive at baseline (≥1.25 gpELISA units/mL for VZV), the 
following parameters and 95% CIs will be summarized at Postvaccination 1 by 
vaccination group: the GMT, the antibody response rate, the GMFR from baseline, 
and the percent of subjects with ≥4-fold rise in antibody titer from baseline.  Similar 
methodology, as described previously, will be used for this summary.  This will be 
computed on the PP and FAS populations (in subjects with baseline VZV antibody 
titer ≥1.25 gpELISA units/mL).  The CIs will only be calculated if there are at least 
5 subjects who are seropositive to a respective antigen.

For subjects in the PP population only, graphical displays of the reverse cumulative 
distribution function of antibody titers will be illustrated by vaccination group.
The key immunogenicity analyses are summarized in Table 3.
 
 
04S63N
 
 
055D6R

Product:  V210 
50
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Table 3
Analysis Strategy for Key Immunogenicity Variables
Endpoint/Variable
(Description, Time Point)
Primary vs 
Supportive 
Approach†
Statistical Method
Analysis 
Population
Missing Data 
Approach
Primary (Hypothesis 1 & 2):
Noninferiority of the
Postvaccination 1 VZV 
antibody response rates in 
Group 1 compared with 
Group 2
P (PP)
S (FAS)
Miettinen and 
Nurminen‡ approach; 
tested at α = 0.025 
(1-sided); corresponding 
95% CIs for risk 
difference
PP
FAS
Observed data 
only
Noninferiority of the 
Postvaccination 1 VZV 
antibody GMTs in Group 1 
compared with Group 2 
P (PP)
S (FAS)
2-sample mean 
difference and 95% CI 
and p values based on 
log-transformed titers 
and t-distribution
PP
FAS
Observed data 
only
Primary (Hypothesis 3):
Acceptability of the 
Postvaccination 1 VZV 
antibody response rate in 
Group 1
P (PP)
S (FAS)
Exact 1-sample binomial; 
tested at α = 0.025 (1-
sided); corresponding 
95% CIs
PP
FAS
Observed data 
only
Secondary:
Summary of 
Postvaccination 1, VZV 
antibody response rates and 
VZV seroconversion rates 
for both groups
P (PP)
S (FAS)
Exact 1-sample binomial 
methodology, 95% CIs
PP
FAS
Observed data 
only
Summary of 
Postvaccination 1 VZV 
antibody GMTs
P (PP)
S (FAS)
1-sample mean and 95% 
CI based on 
log-transformed titers 
and t-distribution
PP
FAS
Observed data 
only
Summary of 
Postvaccination 1 VZV 
antibody response rates, 
GMTs, GMFR from baseline 
and % ≥4-fold rise from 
baseline in subjects initially 
seropositive for both groups
P (PP)
S (FAS)
For rates, 1-sample 
binomial methodology, 
95% CI
For continuous variables, 
one-sample mean and 
95% CI based on t-
distribution
PP
FAS
Observed data 
only
†P = primary approach; S = supportive approach.
‡Miettinen and Nurminen method [17].
 
 
04S63N
 
 
055D6R

Product:  V210 
51
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Statistical Methods for Safety Analysis
8.6.2
Safety and tolerability will be assessed by clinical review of all safety data collected 
throughout the trial.
The analysis of safety results will follow a tiered approach (Table 4).  The tiers differ with 
respect to the analyses that will be performed.  Safety parameters or adverse experiences of 
particular interest that are identified a priori constitute “Tier 1” safety endpoints that will be 
subject to inferential testing for statistical significance with p values and 95% CIs provided 
for between-group comparisons.  Other safety parameters will be considered Tier 2 or Tier 3.  
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for 
between-group comparisons; only point estimates by vaccination group are provided for 
Tier 3 safety parameters.
Any adverse experiences (specific terms as well as system organ class [SOC] terms) that are 
not pre-specified as endpoints of particular interest will be classified as belonging to Tier 2 or 
Tier 3, based on the number of events observed.  Membership in Tier 2 requires that at least 
4 subjects in any vaccination group exhibit the event; all other adverse experiences will 
belong to Tier 3.
The threshold of at least 4 events was chosen because the 95% CI for the between-group 
difference in percent incidence will always include zero when treatment groups of equal size 
each have less than 4 events and, thus, would add little to the interpretation of potentially 
meaningful differences. Because many 95% CIs may be provided without adjustment for 
multiplicity, the CIs should be regarded as a helpful descriptive measure to be used in 
review, not a formal method for assessing the statistical significance of the between-group 
differences in adverse experiences and predefined limits of change.
For this protocol, the following are considered Tier 1 events: elevated temperatures 
(maximum reported temperature ≥102.2°F [≥39.0°C] oral equivalent) within Days 1 to 42 
after each vaccination; vaccine-specific measles-, rubella-, varicella-, zoster-like rashes, 
mumps-like symptoms, and injection-site rashes occurring within Days 1 to 42 after each 
vaccination; and solicited injection-site reactions (redness, swelling, pain/tenderness) within 
Days 1 to 5 after each vaccination.  In addition, the broad clinical categories consisting of the 
percentage of subjects with any adverse experience, a vaccine-related adverse experience, a 
serious adverse experience, an adverse experience that is both vaccine-related and serious, 
and who discontinued due to an adverse experience will be considered Tier 2 endpoints.  The 
p values (Tier 1 only) and 95% CIs (Tier 1 and Tier 2) will be provided for between-group 
differences in the percentage of subjects with events; these analyses will be performed using 
the Miettinen and Nurminen method, an unconditional, asymptotic method [17].
Extended Safety Follow-up Period (Day 133 [+14 days] to Day 271 [+14 days])
For the extended safety follow-up period, a summary will be provided of the number of 
subjects in each vaccination group who report a serious adverse experience or a medically 
attended adverse experience.  For this extended safety follow-up period, these events will be 
treated as Tier 2 events, with 95% CIs being presented for the between-group risk differences 
in the percentage of subjects reporting these events.  For serious adverse experiences, a 
 
 
04S63N
 
 
055D6R

Product:  V210 
52
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
summary along with a between-group comparison will also be provided for the entire trial
(i.e., from enrollment through 180 days Postvaccination 2).
Because many 95% CIs may be provided without adjustment for multiplicity, the CIs should 
be regarded as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance of the between-group differences in adverse experiences.
Table 4
Analysis Strategy for Safety Parameters
Safety Tier
Safety Endpoint†
p Value
95% CI for 
Treatment 
Comparison
Descriptive 
Statistics
Tier 1
Rate of elevated temperatures
(102.2F [39.0C]) ‡
from Days 1 to 42 postvaccination
X
X
X
Vaccine-specific systemic rashes 
(measles-like, rubella-like, varicella-
like, zoster-like), mumps-like 
symptoms, and injection-site rashes
Days 1 to 42 postvaccination
X
X
X
Injection-site reactions (redness, 
swelling, and pain/tenderness) Days 1 
to 5 postvaccination
X
X
X
Tier 2
Any AE Days 1 to 42 postvaccination
X
X
Any serious AE Days 1 to 42 
postvaccination
X
X
Any vaccine-related§ AE Days 1 to 42 
postvaccination
X
X
Any serious and vaccine-related§ AE
Days 1 to 42 postvaccination
X
X
Discontinuation due to AE Days 1 to 
42 postvaccination
X
X
Specific systemic AEs¶ and SOCs
(incidence ≥4 subjects in one of the 
vaccination groups) during Days 1 to 
42 postvaccination and injection-site 
reactions¶ (incidence ≥4 subjects in 
one of the vaccination groups) Days 1 
to 5 postvaccination and Days 1 to 42 
postvaccination
X
X
 
 
04S63N
 
 
055D6R

Product:  V210 
53
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Safety Tier
Safety Endpoint†
p Value
95% CI for 
Treatment 
Comparison
Descriptive 
Statistics
Tier 3
Specific systemic AEs¶ and SOCs 
(incidence <4 subjects in all of the 
vaccination groups) during Days 1 to 
42 postvaccination and injection-site 
reactions¶ (incidence <4 subjects in all
of the vaccination groups) Days 1 to 5 
and Days 1 to 42 postvaccination
X
Maximum temperature summary 
(Brighton Collaboration Cutpoints) by 
day range: Days 1 to 42, Days 1 to 5, 
Days 6 to 13, Days 14 to 28, and Days 
29 to 42 postvaccination
X
Distribution of maximum size (for 
injection-site redness and swelling
Days 1 to 5 postvaccination) and 
distribution of maximum intensity (for 
all other injection-site reactions
Days 1 to 5 postvaccination and all 
systemic AEs Days 1 to 42
postvaccination)
X
† Adverse experience references refer to Clinical AEs.
‡ For reporting purposes, temperatures will be converted to oral equivalent by adding 1.0°F to axillary 
temperatures and subtracting 1.0°F from rectal temperatures.
§ Determined by the investigator to be related to the vaccine.
¶ Includes only those endpoints not pre-specified as Tier 1 or not already pre-specified as Tier-2 endpoints.
X = results will be provided.
The between-group comparisons described above will be made between Group 1 and 
Group 2 for each postvaccination follow-up period.  This will be done by performing 
separate comparisons between VARIVAX™ PE34 process and VARIVAX™ (2016 
commercial product) vaccination groups for the 42 days after receipt of the first vaccination 
and for the 42 days after receipt of the second vaccination. For serious adverse experiences, 
a summary along with a between-group comparison will also be provided for the entire 
primary trial phase (i.e., the combined 42-day periods after both vaccinations).
Summaries of Baseline Characteristics, Demographics, and Other Analyses
8.6.3
Subject characteristics of age, gender, and race/ethnicity will be summarized by vaccination 
group for all subjects who entered the trial.  In addition, baseline serostatus for VZV will be 
presented by vaccination group.
The number (%) of subjects with specific prior medications in any vaccination group within 
14 days before the first vaccination will be summarized by vaccination group.  Also, the 
number (%) of subjects with specific prior vaccinations (incidence rate >0% in any 
vaccination group) within 14 days before each vaccination will be summarized.
 
 
04S63N
 
 
055D6R

Product:  V210 
54
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
The number (%) of subjects with specific concomitant medications (incidence rate ≥5% in 
any vaccination group) within 42 days after each visit will be summarized by vaccination 
group.  Also, the number (%) of subjects with specific concomitant vaccinations (incidence 
rate >0% in any vaccination group) within 42 days after each visit will be summarized by 
vaccination group.
No statistical comparisons will be made between vaccination groups.  Instead, balance 
between vaccination groups with respect to subject characteristics will be determined by 
observation.
A detailed subject accounting will be provided at each vaccination visit and for each 
follow-up period.  This accounting will describe the number of subjects randomized at trial
start, the number vaccinated at each vaccination visit, and the number of discontinuations and 
withdrawals during each safety follow-up period.  This subject accounting will also indicate 
the number of subjects who completed the trial.
No other analyses are planned for this trial.
Interim Analyses
8.7
No interim analyses are planned for this trial.
Multiplicity
8.8
Because success of the trial requires success on both the noninferiority and acceptability
hypotheses, no adjustment for multiplicity is required across the hypothesis tests.
Sample Size and Power Calculations
8.9
Sample Size and Power for Immunogenicity Analyses
8.9.1
This trial will randomize ~300 subjects into Group 1 (VARIVAX™ PE34 process) and 
~300 subjects into Group 2 (VARIVAX™ [2016 commercial product]), and this trial has 
94.1% power for demonstrating noninferiority of the VZV response rate, 95.8% power for 
demonstrating noninferiority for antibody GMTs, and >99.9% power for demonstrating 
acceptability of the VZV response rate at an overall 1-sided 2.5% α -level.
The sample size and power calculations are based on the following assumptions:

10% of subjects will be nonevaluable after the first vaccination (due to lost to 
follow-up or other reasons, excluding baseline VZV serostatus),

For the VZV analysis, 10% will have baseline VZV antibody titers 
>1.25 gpELISA units/mL, resulting in an expected overall nonevaluability rate for the 
VZV Postvaccination 1 primary analyses of 20% ( = 10% + 10%), and

The expected VZV Postvaccination 1 response rate in both groups is assumed to be 
90% based on prior experience with VARIVAX™ in this age group.

The assumed standard deviation of the log-transformed VZV antibody titer is 1.2 
based on previous studies of VARIVAX™.
 
 
04S63N
 
 
055D6R

Product:  V210 
55
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
If the assumptions listed above are observed at the final analysis, the lower bounds for the 
95% CIs for addressing the 3 primary hypotheses listed in Section 8.6.1 would be −5.4% for 
the noninferiority of response rates comparison (Hypothesis 1), 0.81 for the noninferiority of 
GMTs comparison (Hypothesis 2), and 86.2% for the acceptability of the response rate 
(Hypothesis 3).
Because success of the trial requires that the statistical criteria be met for both the 
noninferiority and acceptability
hypotheses, the overall power for the primary 
immunogenicity hypotheses is estimated to be 90% ( = 0.941 × >0.999 × 0.958).
Sample Size and Power for Safety Analyses
8.9.2
For safety comparisons Postvaccination 1, all subjects are expected to be evaluable. If no 
serious adverse event is observed among the 300 subjects in each vaccination group, this trial 
provides 97.5% confidence that the true serious adverse event rate is <1.22% (1 out of every 
81 subjects).
The probability of observing at least 1 serious adverse event in this trial depends on the 
number of subjects enrolled and the incidence rate of serious adverse events in the general 
population.  If the incidence rate of a serious adverse event is 1 of every 186 recipients of the 
vaccine (0.54%), then there is an 80% chance of observing at least 1 such serious adverse 
event among 300 subjects in the vaccine group. 
If the incidence rate is 1 of every 
433 recipients (0.23%), there is a 50% chance of observing at least 1 serious adverse event.
For safety comparisons, risk differences between any 2 vaccination groups that could be 
detected with an 80% probability are summarized in Table 5 for a variety of hypothetical true 
incidence rates.  These calculations assume there are 300 subjects for safety in both groups 
and are based on a 2-sided significance level of α = 0.05.  No multiplicity adjustments were 
made in these calculations.
Table 5
Differences in Incidence of Adverse Event Rates between the Two Vaccination 
Groups That Can be Detected With an ~80% Probability and a Two-Sided 
Significance Level of 0.05 Postvaccination 1
True Incidence Rate of Adverse 
Events in the Control Group 
(Group 2)
True Incidence Rate of Adverse 
Events in the Investigational Group 
(Group 1)
Detectable Percentage 
Point Difference in 
Incidence Rates of 
Adverse Events
N = 300
N = 300
1%
4.8%
3.8
2%
6.6%
4.6
5%
11.2%
6.2
10%
17.9%
7.9
15%
24.0%
9.0
20%
29.9%
9.9
30%
40.9%
10.9
 
 
04S63N
 
 
055D6R

Product:  V210 
56
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
For safety comparisons Postvaccination 2, it is expected that ~5% of subjects will fail to 
return for the second vaccination phase, which results in 285 subjects in each group. If no 
serious adverse event is observed among the 285 subjects in each vaccination group, this trial 
provides 97.5% confidence that the true serious adverse event rate is <1.29% (1 out of every 
77 subjects).
The probability of observing at least 1 serious adverse event in this trial depends on the 
number of subjects enrolled and the incidence rate of serious adverse events in the general 
population.  If the incidence rate of a serious adverse event is 1 of every 177 recipients of the 
vaccine (0.56%), then there is an 80% chance of observing at least 1 such serious adverse 
event among 285 subjects in the vaccine group. 
If the incidence rate is 1 of every 
411 recipients (0.24%), there is a 50% chance of observing at least 1 serious adverse event.
For safety comparisons, risk differences between any 2 vaccination groups that could be 
detected with an 80% probability are summarized in Table 6 for a variety of hypothetical true 
incidence rates.  These calculations assume there are 285 subjects for safety in both groups 
and are based on a 2-sided significance level of α = 0.05.  No multiplicity adjustments were 
made in these calculations.
Table 6
Differences in Incidence of Adverse Event Rates Between the Two Vaccination 
Groups That Can be Detected With an ~80% Probability and a Two-Sided 
Significance Level of 0.05 Postvaccination 2
True Incidence Rate of Adverse 
Events in the Control Group 
(Group 2)
True Incidence Rate of Adverse 
Events in the Investigational 
Group (Group 1)
Detectable Percentage Point 
Difference in Incidence Rates 
of Adverse Events
N=285
N=285
1%
5.0%
4.0
2%
6.8%
4.8
5%
11.4%
6.4
10%
18.1%
8.1
15%
24.3%
9.3
20%
30.2%
10.2
30%
41.2%
11.2
Subgroup Analyses
8.10
To determine whether the vaccination effect is consistent across various subgroups, the 
estimate of the between-group effect (with a nominal 95% CI) for the primary 
immunogenicity endpoints will be estimated and may be plotted within each category of the 
following classification variables:

Sex (female, male)

Race
 
 
04S63N
 
 
055D6R

Product:  V210 
57
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
The consistency of the vaccination effect will be assessed descriptively via summary 
statistics by category for the classification variables listed above.
In addition, a summary of Tier 1 and Tier 2 adverse experiences will be provided for sex and 
race.
Extent of Exposure
8.11
The number of subjects vaccinated at each vaccination visit will be summarized by 
vaccination group.
9.0 LABELING, PACKAGING,
STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product
9.1
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided by the Sponsor as summarized in Table 7.
Table 7
Product Descriptions
Product Name
Dosage Form
Varicella Virus Vaccine Livea
PE34 
processb
Single 0.5 mL dose suspension for subcutaneous injection after 
reconstitution
Varicella Virus Vaccine Livea,b (2016 
commercial product)
Single 0.5 mL dose suspension for subcutaneous injection after 
reconstitution
Measles, Mumps, and Rubella Virus 
Vaccine Liveb,c
Single 0.5 mL dose suspension for subcutaneous injection after 
reconstitution
Sterile Diluent for Reconstitution of Merck 
Live Virus Vaccines (Sterile Water)
0.7 mL sterile solution for reconstitution
aVaricella Virus Vaccine Live = VARIVAX™.
bPotency conforms to product standards as stated in the respective product inserts.
cMeasles, Mumps, and Rubella Virus Vaccine Live = M-M-R™ II.
Packaging and Labeling Information
9.2
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirements.
Blinded, single-dose vials of VARIVAX™ PE34 process and VARIVAX™ (2016 
commercial product) will be supplied to the clinical sites. Open-label, single-dose vials of M-
M-R™ II and Sterile Diluent for reconstitution will be supplied to the clinical sites.  No 
subject-specific kitting is required.
 
 
04S63N
 
 
055D6R

Product:  V210 
58
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Clinical Supplies Disclosure
9.3
The emergency unblinding call center will use the treatment/randomization schedule for the 
trial to unblind subjects and to unmask vaccine identity.  In the event that the emergency 
unblinding call center is not available for a given site in this trial, the central electronic 
treatment allocation/randomization system (IVRS/IWRS) should be used in order to unblind 
subjects and to unmask treatment/vaccine identity. The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supplies.
Storage and Handling Requirements
9.4
Clinical supplies must be stored in a secure, limited-access location under the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may not be used for any purpose other than that stated in the protocol.
Discard/Destruction/Returns and Reconciliation
9.5
The investigator is responsible for keeping accurate records of the clinical supplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. For all trial sites, the local country Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability and return, or local discard and destruction if appropriate.  Where local 
discard and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented.
Standard Policies
9.6
Trial 
site 
personnel 
will 
have 
access 
to 
a 
central 
electronic 
treatment 
allocation/randomization system (IVRS/IWRS system) to allocate subjects, to assign vaccine
to subjects and to manage the distribution of clinical supplies. Each person accessing the 
IVRS system must be assigned an individual unique PIN.  They must use only their assigned 
PIN to access the system, and they must not share their assigned PIN with anyone.
10.0 ADMINISTRATIVE AND REGULATORY DETAILS
Confidentiality
10.1
Confidentiality of Data
10.1.1
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employees, only under an appropriate 
understanding of confidentiality with such board or committee, affiliated institution and 
 
 
04S63N
 
 
055D6R

Product:  V210 
59
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
employees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records
10.1.2
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory authority representatives may consult and/or copy trial documents in 
order to verify worksheet/case report form data.  By signing the consent form, the subject 
agrees to this process.  If trial documents will be photocopied during the process of verifying 
worksheet/case report form information, the subject will be identified by unique code only; 
full names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information
10.1.3
By signing this protocol, the investigator recognizes that certain personal identifying 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory 
submissions, and as required by law.  This information may include:
1. name, address, telephone number and e-mail address;
2. hospital or clinic address and telephone number;
3. curriculum vitae or other summary of qualifications and credentials; and
4. other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country and other 
countries, including countries that do not have laws protecting such information.  
Additionally, the investigator’s name and business contact information may be included 
when reporting certain serious adverse events to regulatory authorities or to other 
investigators.  By signing this protocol, the investigator expressly consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor 
may share an investigator’s name and contact information with other participating 
investigators upon request.
 
 
04S63N
 
 
055D6R

Product:  V210 
60
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Confidentiality of IRB/IEC Information
10.1.4
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by those agencies.
Compliance with Financial Disclosure Requirements
10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility to comply with any such request.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment
10.3
By signing this protocol, the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by Merck, is provided in Section 12.1 -
Merck Code of Conduct for Clinical Trials.
The investigator also agrees to allow monitoring, audits, IRB/IEC review and regulatory 
authority inspection of trial-related documents and procedures and provide for direct access 
to all trial-related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator by the Sponsor.
 
 
04S63N
 
 
055D6R

Product:  V210 
61
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by this protocol or as otherwise required pursuant to any agreement with 
the Sponsor.
Trial documentation will be promptly and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the trial site upon request for inspection, 
copying, review and audit at reasonable times by representatives of the Sponsor or any 
regulatory authorities.  The investigator agrees to promptly take any reasonable steps that are 
requested by the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copies of all documentation and records relating to the 
conduct of the trial in compliance with all applicable legal and regulatory requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory reference ranges, laboratory certification or 
quality control procedures and laboratory director curriculum vitae.  By signing this protocol, 
the investigator agrees that documentation shall be retained until at least 2 years after the last 
approval of a marketing application in an ICH region or until there are no pending or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigational product.  
Because the clinical development and marketing application process is variable, it is 
anticipated that the retention period can be up to 15 years or longer after protocol database 
lock. The Sponsor will determine the minimum retention period and notify the investigator 
when documents may be destroyed.  The Sponsor will determine the minimum retention 
period and upon request, will provide guidance to the investigator when documents no longer 
need to be retained.  The Sponsor also recognizes that documents may need to be retained for 
a longer period if required by local regulatory requirements. All trial documents shall be 
made available if required by relevant regulatory authorities. The investigator must consult 
with and obtain written approval by the Sponsor prior to destroying trial and/or subject files.  
ICH Good Clinical Practice guidelines recommend that the investigator inform the subject’s 
primary physician about the subject’s participation in the trial if the subject has a primary 
physician and if the subject agrees to the primary physician being informed.
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by any court or regulatory 
authority will not be allowed to conduct or work on this Sponsor’s trials.  The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
 
 
04S63N
 
 
055D6R

Product:  V210 
62
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
In the event the Sponsor prematurely terminates a particular trial site, the Sponsor will 
promptly notify that trial site’s IRB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator for a multi-center trial (including multinational).  When more than one trial site 
is open in an EU country, Merck, as the Sponsor, will designate, per country, a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single-center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator to review the 
trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accurately describes the conduct and results of the trial [Clinical Study 
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availability of the Protocol/CSR 
CI during the anticipated review process, thorough understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI must be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements
10.4
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely responsible for determining whether the trial and its results are subject to 
the 
requirements 
for 
submission 
to 
http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  Merck, as Sponsor of this trial, will 
review this protocol and submit the information necessary to fulfill these requirements. 
Merck entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify potentially appropriate trials for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropriate trial locations and trial site contact information.  
By signing this protocol, the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System
10.5
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
 
 
04S63N
 
 
055D6R

Product:  V210 
63
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Data Management
10.6
The investigator or qualified designee is responsible for recording and verifying the accuracy 
of subject data.  By signing this protocol, the investigator acknowledges that his/her 
electronic signature is the legally binding equivalent of a written signature.  By entering 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
Publications
10.7
This trial is intended for publication, even if terminated prematurely. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become available, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines may be extended on 
OTC trials.  For trials intended for pediatric-related regulatory filings, the investigator agrees 
to delay publication of the trial results until the Sponsor notifies the investigator that all 
relevant regulatory authority decisions on the trial drug have been made with regard to 
pediatric-related regulatory filings. Merck will post a synopsis of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the 
primary outcome, 12 months after the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property, or to comply with confidentiality 
agreements with other parties.  Authors of the primary results manuscript will be provided 
the complete results from the Clinical Study Report, subject to the confidentiality agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy is to also 
include the protocol and statistical analysis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy and safety measures, the statistical analysis plan, and any amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independently.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should always be described in such a manuscript.
 
 
04S63N
 
 
055D6R

Product:  V210 
64
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, 2 and 3.  Significant contributions to trial 
execution may also be taken into account to determine authorship, provided that 
contributions have also been made to all three of the preceding authorship criteria.  Although 
publication planning may begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrity of the data, method(s) of data analysis and the scientific content of the manuscript.
The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45 days prior to submission for publication/presentation. 
Any information identified by the Sponsor as confidential must be deleted prior to 
submission; this confidentiality does not include efficacy and safety results. Sponsor review 
can be expedited to meet publication timelines.
 
 
04S63N
 
 
055D6R

Product:  V210 
65
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
11.0 LIST OF REFERENCES
[1]
Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin 
North Am 1996;10(3):571-81.
[2]
Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United 
States, 1988 to 1999.[Article]. Pediatr Infect Dis J 2002;21(10):931-4.
[3]
Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before 
vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182:383-90.
[4]
Kuter BJ, Weibel RE, Guess H, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck 
varicella vaccine in healthy children:  final report of a 2-year efficacy study and 7-
year follow-up studies. Vaccine 1991;9(9):643-7.
[5]
Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, Chaves SS, et al. 
Changing varicella epidemiology in active surveillance sites-United States, 1995-
2005. J Infect Dis 2008;197(Suppl 2):S71-S75.
[6]
Luman ET, Ching PLYH, Jumaan AO, Seward JF. Uptake of varicella vaccination 
among young children in the United States: A success story in eliminating racial and 
ethnic disparities. Pediatr 2006;117(4):999-1008.
[7]
Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of Varicella 
Vaccination on Health Care Utilization. JAMA 2005;294(7):797-802.
[8]
Centers for Disease Control. Prevention of varicella:  recommendations of the 
advisory committee on immunization practices (ACIP). MMWR 2007;56(RR-4):1-
CE-4.
[9]
Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US after 
implementation of the vaccination program. Pediatrics 2011;128:214-20.
[10]
Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Long-term 
effectiveness of varicella vaccine: A 14-year, prospective cohort study. Pediatrics 
2013;131(5):1-8.
[11]
Centers for Disease Control and Prevention. Recommended immunization schedules 
for persons aged 0--18 years---United States, 2007. MMWR 2007;55(51):Q1-Q4.
[12]
White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, et al. 
Modified cases of chickenpox after varicella vaccination: correlation of protection 
with antibody response. Pediatr Infect Dis J 1992;11(1):19-23.
 
 
04S63N
 
 
055D6R

Product:  V210 
66
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
[13]
Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual 
varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in 
ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 
1986;14:177-88.
[14]
Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for 
antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med 
Virol 1990;32:189-93.
[15]
Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Wasmuth EH, et al. 
Antibody assays suitable for assessing immune responses to live varicella vaccine. 
Vaccine 1991;9:111-6.
[16]
Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing 
antibody responses to Oka/Merck live varicella vaccine (VARIVAX®) in children 
and adults. Vaccine 1997;15(1):61-4.
[17]
Miettinen O, Nurminen M. Comparative analysis of two rates. Statistics in Medicine 
1985;4:213-26.
[18]
Collett D. Statistical inference for binary data. In: Collett D, ed. Modelling Binary 
Data. New York: Chapman & Hall, 1999:17-42.
 
 
04S63N
 
 
055D6R

Product:  V210 
67
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
12.0 APPENDICES
Merck Code of Conduct for Clinical Trials
12.1
Merck*
Code of Conduct for Clinical Trials
I.
Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator-initiated trials which are not under the control of Merck.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
Merck selects investigative sites based on medical expertise, access to appropriate subjects, adequacy of facilities 
and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by Merck personnel to assess the ability to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, completeness and consistency. Data are verified versus source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP-non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts.  Some early phase or 
pilot trials are intended to be hypothesis-generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of multiplicity.
Merck’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications. 
 
 
04S63N
 
 
055D6R

Product:  V210 
68
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
III. Subject Protection
A. IRB/ERC review
All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that 
changes required urgently to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form. 
B. Safety
The guiding principle in decision-making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are never denied access to appropriate medical care 
based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a Merck trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
Merck is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by law, 
only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by name.  
D. Genomic Research
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time- and labor-intensive.  It is Merck’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of Merck trials.  Merck does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made 
to compensate for the time spent in extra recruiting efforts.
Merck does not pay for subject referrals.  However, Merck may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B. Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V. Investigator Commitment
Investigators will be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "Merck" refers to Merck Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc."
 
 
04S63N
 
 
055D6R

Product:  V210 
69
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Collection and Management of Specimens for Future Biomedical Research
12.2
1. Definitions
a.
Biomarker:  A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used to see how well the body responds to a treatment for a disease or condition.1
b. Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.
Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d. DNA:  Deoxyribonucleic acid.
e.
RNA:  Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section 7.1.3.2 –
Future Biomedical Research Samples will be used in various experiments to understand:
o
The biology of how drugs/vaccines work
o
Biomarkers responsible for how a drug/vaccine enters and is removed by the body
o
Other pathways drugs/vaccines may interact with
o
The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by the Sponsor or those working for 
or with the Sponsor.
3. Summary of Procedures for Future Biomedical Research
a.
Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered for enrollment in the 
Future Biomedical Research sub-trial.
b. Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by the investigator or his or her designate.  Informed consent for Future 
Biomedical Research should be presented to the subjects on the visit designated in the 
trial flow chart.  If delayed, present consent at next possible Subject Visit.  Consent 
forms signed by the subject will be kept at the clinical trial site under secure storage 
for regulatory reasons.  
 
 
04S63N
 
 
055D6R

Product:  V210 
70
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
A template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.
eCRF Documentation for Future Biomedical Research Specimens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroyed.
d. Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually be obtained at a time 
when the subject is having blood drawn for other trial purposes.
4. Confidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with future test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analyses to be conducted. Knowing subject 
characteristics like gender, age, medical history and treatment outcomes are critical to 
understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
specimens will be single-coded per ICH E15 guidelines as described below. 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between subject identifiers 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices.  Analyses utilizing the Future Biomedical Research specimens may be 
performed by the Sponsor, or an additional third party (e.g., a university investigator) 
designated by the Sponsor. The investigator conducting the analysis will follow the 
Sponsor’s privacy and confidentiality requirements. Any contracted third party analyses 
will conform to the specific scope of analysis outlined in this sub-trial. Future Biomedical 
Research specimens remaining with the third party after specific analysis is performed 
will be reported to the Sponsor.
6. Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research.  Subjects may withdraw 
consent at any time by contacting the principal investigator for the main trial. If medical 
records for the main trial are still available, the investigator will contact the Sponsor 
using 
the 
designated 
mailbox 
(clinical.specimen.management@merck.com). 
 
 
04S63N
 
 
055D6R

Product:  V210 
71
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Subsequently, the subject's specimens will be flagged in the biorepository and restricted 
to main study use only. If specimens were collected from study participants specifically 
for Future Biomedical Research, these specimens will be removed from the biorepository 
and destroyed. Documentation will be sent to the investigator confirming withdrawal 
and/or destruction, if applicable. It is the responsibility of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progress at the time of request for withdrawal/destruction or already performed prior to 
the request being received by the Sponsor will continue to be used as part of the overall 
research trial data and results. No new analyses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory authorities to retain the main trial 
records) or the specimens have been completely anonymized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository for potential 
analysis for up to 20 years from the end of the main study. Specimens may be stored for 
longer if a regulatory or governmental authority has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequately addressed.
Specimens from the trial site will be shipped to a central laboratory and then shipped to 
the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular 
trial, the trial site will ship directly to the Sponsor-designated biorepository. The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure the integrity of the specimens.  Specimens will be destroyed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository database.
8. Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Subjects
No information obtained from exploratory laboratory studies will be reported to the 
subject, family, or physicians. Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predictive capability, 
and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly report this information to doctors and subjects.  Subjects will not be identified by 
 
 
04S63N
 
 
055D6R

Product:  V210 
72
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
name in any published reports about this study or in any other scientific publication or 
presentation.
10. Future Biomedical Research Study Population
Every effort will be made to recruit all subjects diagnosed and treated on Sponsor clinical 
trials for Future Biomedical Research.
11. Risks Versus Benefits of Future Biomedical Research 
For future biomedical research, risks to the subject have been minimized. Buccal swab 
specimens will be collected inside the cheek with no associated venipuncture to obtain 
the specimen. Therefore, there will not be an additional risk for the subject.
The Sponsor has developed strict security, policies and procedures to address subject data 
privacy concerns.  Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality.  In this highly unlikely situation there is risk that the 
information, like all medical information, may be misused.
12. Questions
Any questions related to the future biomedical research should be e-mailed directly to 
clinical.specimen.management@merck.com.
13. References
1. National Cancer Institute: http://www.cancer.gov/dictionary/?searchTxt=biomarker
2. International Conference on Harmonization: DEFINITIONS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA 
AND 
SAMPLE 
CODING 
CATEGORIES 
-
E15; 
http://www.ich.org/LOB/media/MEDIA3383.pdf
3. Industry Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i-pwg.org/
4. Industry Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i-pwg.org/
 
 
04S63N
 
 
055D6R

Product:  V210 
73
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Approximate Blood Volumes Collected by Trial Visit and by Sample Types
12.3
Trial Visit
Visit 1
Visit 2
Visit 3
Visit 4
Blood for immunogenicity testing
3
3
—
—
Expected total (mL)
3
3
—
—
 
 
04S63N
 
 
055D6R

Product:  V210 
74
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Scripted Questionnaire to Be Used by Site Personnel to Obtain Serious Adverse 
12.4
Experience and Medically Attended Adverse Event Information
The following script is to be used at the Phone Call at Day 271 (180 days after Dose 2) in 
order to probe for any serious adverse experiences and medically attended adverse events 
that were not previously reported by the subject's parent/legally acceptable representative 
from Visit 4 (Day 133) through Day 271.
It is the responsibility of the Investigator to carefully assess the information and make a 
determination whether the adverse experience meets one or more criteria for being reported 
as a serious adverse experience. Serious adverse experiences and medically attended adverse 
events identified through the interview process should be reported to the Sponsor/Sponsor
Representative.
Questionnaire:
Since the last visit,
1. Has your child been admitted to a hospital?
2. Has your child experienced a life-threatening episode or an important medical event 
that required attendance in the Emergency Room or a health care provider’s office?
3. Has your child seen your doctor, nurse, or health care provider for any other reason 
other than a well-child visit?
4. Did your child have any medical conditions before you agreed to participate in the 
trial that have become worse or have required more frequent visits to a health care 
provider since the last visit?
5. Has your child developed cancer?
6. Has your child developed a new medical condition that I am not aware of?
If the answer to any of the questions above is “yes”, the interviewer will determine if the 
event is a serious adverse experience or a medically attended event and if so, will gather all 
related information and transcribe onto the appropriate eCRFs.
For each serious adverse experience that is identified through the interview process, 
information from all available sources, including subject/legally acceptable representative
report, subject medical records, hospital discharge summary, and death certificate should be 
sought to provide a complete description of the adverse experience. All pertinent information 
must be recorded in the database and retained in the subject’s file including, but not limited 
to:

Serious adverse experience term

Onset date

Causality

Outcome
 
 
04S63N
 
 
055D6R

Product:  V210 
75
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential

The seriousness criteria that the adverse experience met:
−
death 
−
caused hospitalization or prolonged existing hospitalization
−
persistent or significant disability
−
life-threatening adverse experience
−
cancer
−
due to an overdose
−
congenital anomaly
−
other medical adverse experience

Hospitalization admission date

Hospital discharge date

Concomitant medications/vaccinations or changes in concomitant medications 
associated with the serious adverse experience

Concurrent conditions

Other medical history

Procedures associated with the serious adverse experience

Laboratory results
 
 
04S63N
 
 
055D6R

Product:  V210 
76
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
List of Abbreviations and Definitions of Terms
12.5
Term
Definition
ACIP
Advisory Committee on Immunization Practices
AE
adverse event or adverse experience (used interchangeably)
ASaT
All Subjects As Treated
CI
confidence interval
CID
component identification number
CSR
clinical study report
DOD
delta optical density
DTaP
Diphtheria, Tetanus, and Acellular Pertussis
DNA
deoxyribonucleic acid
ECI
event of clinical interest
eCRF
electronic case report form
EDC
electronic data capture
EU
European Union
FDA
Food and Drug Administration
FSA
full analysis set
GCP
Good Clinical Practice
GMFR
geometric mean fold rise
GMT
geometric mean titer
gp
glycoprotein
gpELISA
glycoprotein enzyme-linked immunosorbent assay
Hib
Haemophilus influenzae type b
HIV
human immunodeficiency virus
HZ
herpes zoster
IgG
immunoglobulin G
IPV
inactivated poliovirus
IRB
institutional review board
IVRS
interactive voice response system
IWRS
integrated web response system
M M-R™ II
measles, mumps, and rubella virus vaccine live, Merck
 
 
04S63N
 
 
055D6R

Product:  V210 
77
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
Term
Definition
OD
optical density
PP
Per-protocol Population
PRO
patient-reported outcome
ProQuad™
measles, mumps, rubella, and varicella virus vaccine live, Merck
SD
standard deviation
SOC
system organ class
SOP
standard operating procedure
TCC
tissue culture control
VARIVAX™
varicella virus vaccine live (Oka/Merck); A210
eVRC
electronic vaccination report card
VZV
varicella zoster virus
WHO
World Health Organization
ZOSTAVAX™
zoster vaccine live, Merck
 
 
04S63N
 
 
055D6R

Product:  V210 
78
Protocol/Amendment No.: A03-01 
V210-A03-01 Final Protocol
26-Oct-2017
Confidential
13.0 SIGNATURES
Sponsor's Representative
13.1
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
Investigator
13.2
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol (including other manuals and documents 
referenced from this protocol).  I agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0 – TRIAL PROCEDURES (Assessing and Recording Adverse 
Events).  I also agree to handle all clinical supplies provided by the Sponsor and collect and 
handle all clinical specimens in accordance with the protocol.  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary precautions are taken to protect such information from loss, inadvertent disclosure 
or access by third parties.
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
 
 
04S63N
 
 
055D6R